Official Protocol Title:  
NCT number:  [STUDY_ID_REMOVED] 
Document Date:  14-Jul-2022A Phase 2, Randomized, Double-Blind, Multicenter Study to 
Evaluate the Safety and Immunogenicity of Three Different Potency 
Levels of V181 (Dengue Quadrivalent Vaccine rDENVÎ”30 [live, 
attenuated]) in Healthy Adults
PRODUCT: V181  1
PROTOCOL/AMENDMENT NO.: 003-01
V181 -003-01FINAL PROTOCOL 14-JUL-2022
Title Page
THIS PROTOCOL AMENDMENT AND ALL OF THE INFORMATION RELATING 
TO IT ARE CONFIDENTIAL AND PROPRIETARY PROPERTY OF MERCK 
SHARP & DOHME LLC, RAHWAY, NJ, [LOCATION_003] (MSD) .
Protocol Title: A Phase 2, Randomized, Double -Blind, Multicenter Study to Evaluate the 
Safety and Immunogenicity of Three Different Potency Levels of V181 (Dengue 
Quadrivalent Vaccine rDENVÎ”30 [live, attenuated]) in Healthy Adults
Protocol Number: 003-01
Compound Number: V181
Sponsor Name:
[CONTACT_19519] & Dohme LLC
(hereafter called the Sponsor or MSD)
Legal Registered Address:
[ADDRESS_463883], NJ [ZIP_CODE] [LOCATION_003]
Regulatory Agency Identifying Number(s):
IND [ADDRESS_463884] 2020- 004501- 30
Approval Date: [ADDRESS_463885]: V181  2
PROTOCOL/AMENDMENT NO.: 003-01
V181 -003-01FINAL PROTOCOL 14-JUL-2022
Sponsor Signatory
Typed Name:
[CONTACT_1641]:Date
Protocol -specific Sponsor c ontact information can be found in the Investigator Study
File Binder (or equivalent).
Investigator Signatory
I agree to conduct this clinical study in accordance with the design outlined in this protocol 
and to abide by [CONTACT_19373].
Typed Name:
[CONTACT_1641]:Date
08MVGC
08SK8Z
PRODUCT: V181  3
PROTOCOL/AMENDMENT NO.: 003-[ADDRESS_463886]: V181  4
PROTOCOL/AMENDMENT NO.: 003-01
V181 -003-01FINAL PROTOCOL 14-JUL-2022
PROTOCOL AMEN DMENT SUMMARY OF CHANGES
Amendment: 01
Overall Rationale for the Amendments:
The primary reason for the amendment was to provide the potency levels for V181 and to extend the contraception requirements from 
4 weeks after administration of study intervention to 90 days after administration of study intervention .
Summary of Changes Table:
Section # and Name [CONTACT_370820]
1.1 Synopsis
6.1 Study Intervention(s) 
Administered â€“Table 1Added potency levels for each serotype 
being administered for each of the 3 V181 
potency level groups ,and deleted footnote 
about potency levels being â€˜to be 
determined â€™.
Added a footnote to indicate that the 
provided potency levels represent the final 
dose strength for the 0.5 mL dose of V181.Potency levels being administered were previously to 
be determined.
To clarify that the potency levels described represent 
the final dose strength in each 0.5 mL dose of V181.
5.1 Inclusion Criterion No.3
5.1 Inclusion Criterion No. 4Extended contraception requirements from 
4 weeks to 90 days .To reduce the risk of pregnancy in WOCBP who are 
study participants (in accordance to MSD 
specifications for other live virus vaccines, such as 
VARIVAXâ„¢ )or partn ers of male study participants (a 
spermatogenesis cycle is approximately 90 days) .
08MVGC
08SK8Z
PRODUCT: V181  5
PROTOCOL/AMENDMENT NO.: 003-01
V181 -003-01FINAL PROTOCOL 14-JUL-2022
Section # and Name [CONTACT_370821]
10.1.[ADDRESS_463887] for 
Clinical TrialsSponsor entity name [CONTACT_148231]. [COMPANY_006] Sharp & Dohme Corp. underwent an entity 
name [CONTACT_19520] & Dohme 
LLC, Rahway, NJ, [LOCATION_003]. This conversion resulted only 
in an entity name [CONTACT_370822].
1.1 Synopsis
6.1 Study Intervention(s) 
Administered â€“Table 1Changed the intervent ion name [CONTACT_370823] â€˜Diluentâ€™ to â€˜Placeboâ€™.
In the â€˜Useâ€™ column for V181 groups, 
changed â€˜Experimentalâ€™ to â€˜Test Product.â€™To reduce confusion around the study intervention 
being administered in the Placebo Group.
To align with EU CTR.
1.3 Schedule of Activities Added a row for the collection of study-
supplied eVRC devices.To clarify when eVRC devices will be collected.
2.1 Study Rationale
4.2 Scientific Rationale for 
Study Design
4.3 Justification for Dose
6.2.1 Dose PreparationRemov ed placeholder text for the potency 
levels and/or added a cross -reference to the 
study interventions table.To reflect that potency levels are now known and to 
ensure the ease of finding vaccine potency level 
information.
2.2.[ADDRESS_463888]: V181  6
PROTOCOL/AMENDMENT NO.: 003-01
V181 -003-01FINAL PROTOCOL 14-JUL-2022
Section # and Name [CONTACT_11029]  
4.2.2 Rationale for the Use 
of Comparator/Placebo
6 Study Intervention
6.1 Study Intervention(s) 
Administered â€“Table 1
6.2.1 Dose PreparationRemoved references to â€˜diluent,â€™ including 
removing the foot note in Table 1.For consistency when referring to placebo and to 
reduce confusion around placebo and diluent.
5 Study Population Added a statement about the 
confidentiality of collected information.To align with EU CTR.
5.1 Exclusion Criterion No. 
16Changed donation requirements from 
6weeks to 90 days postvaccination.To reduce the risk of viremic participants donating 
blood, eggs, or sperm.
6.1 Study Intervention(s) 
Administered â€“Table 1Deleted footnote about dilution procedures 
for V181 .
Revised the column heading and footnote 
for investigational product from 
â€˜IMP/NIMP â€™ to â€˜IMP or NIMP/AxMPâ€™.To avoid redundancy in the protocol with the detailed 
information that will be provided in the Pharmacy 
Manual .
To align with EU CTR.
[IP_ADDRESS] Withdrawal From 
Future Biomedical Research
10.6 Appendix 6: Collection 
and Management of 
Specimens for Future 
Biomedical ResearchUpdated Sponsor email address for clinical 
specimen management.To align with current email a ddress.
08MVGC
08SK8Z
PRODUCT: V181  7
PROTOCOL/AMENDMENT NO.: 003-01
V181 -003-01FINAL PROTOCOL 14-JUL-2022
Section # and Name [CONTACT_11029]  
8.4Adverse Events, Serious 
Adverse Events, and Other 
Reportable Safety EventsAdded astatement about investigators 
needing to indicate if an event was 
associated with a medication error, misuse, 
or abuse.To align with EU CTR.
10.3 Appendix 3: Adverse 
Events: Definitions and 
Procedures for Recording, 
Evaluating, Follow -up, and 
ReportingAdded a subsection to define medication 
error, misuse, and abuse.To align with EU CTR.
10.3.5 Recording AE and 
SAE â€“Assessment of 
IntensityAdded 2 rows to the AE Intensity Grading 
table to identify which assessments are 
performed for injection site AEs occurring 
on Days 1 through 5 and those occurring 
on Day 6 or later after vaccination. A dded 
a row for â€˜Otherâ€™ injection -site AEs
occurring on Days [ADDRESS_463889]: V181  8
PROTOCOL/AMENDMENT NO.: 003-01
V181 -003-01FINAL PROTOCOL 14-JUL-2022
Section # and Name [CONTACT_370824], 
grammatical, and typographical changes 
were made throughout the document.To ensure clarity and accurate interpretation of the 
intent of the protocol.
08MVGC
08SK8Z
PRODUCT: V181  9
PROTOCOL/AMENDMENT NO.: 003-01
V181 -003-01FINAL PROTOCOL 14-JUL-2022
Table of Contents
DOCUMENT HISTORY ........................................................................................................ 3
PROTOCOL AMENDMENT SUMMARY OF CHANGES ............................................... 4
1 PROTOCOL SUMMARY ............................................................................................ 16
1.1 Synopsis ................................................................................................................. 16
1.2 Schema .................................................................................................................. 20
1.3 Schedule of Activities........................................................................................... 21
2 INTRODUCTION .......................................................................................................... 25
2.1 Study Rationale ....................................................................................................25
2.2 Background .......................................................................................................... 25
2.2.1 Dengue Disease and V181 Development .................................................... 25
2.2.2 Preclinical Studies ........................................................................................ 27
2.2.3 Completed Clinical Studies.......................................................................... 27
[IP_ADDRESS] MSD V181 Completed Studies .......................................................... 27
[IP_ADDRESS] NIH Dengue LATV Complet ed Studies ............................................ 27
[IP_ADDRESS] Butantan- DV Clinical Studies............................................................ 27
2.2.4 Information on Other Study -related Therapy .............................................. 27
2.3 Benefit/Risk Assessment ...................................................................................... 27
3 HYPOTHESES, OBJECTIVES, AND ENDPOINTS ................................................ 28
4 STUDY DESIGN ............................................................................................................ 30
4.1 Overall Design ......................................................................................................30
4.2 Scientific Rationale for Study Design ................................................................ .31
4.2.1 Rationale for Endpoints ............................................................................... 32
[IP_ADDRESS] Immunogenicity Endpoints ................................................................ 32
[IP_ADDRESS] Safety Endpoints ................................................................................ 33
[IP_ADDRESS] Other Exploratory Endpoints ............................................................. 33
[IP_ADDRESS] Future Biomedical Research .............................................................. 33
4.2.2 Rationale for the Use of Comparator/Placebo ............................................. [ADDRESS_463890]: V181  10
PROTOCOL/AMENDMENT NO.: 003-01
V181 -003-01FINAL PROTOCOL 14-JUL-2022
5.5 Participant Replacement Strategy ...................................................................... 39
6 STUDY INTERVENTION ............................................................................................ 39
6.1 Study Intervention(s) Administered ...................................................................40
6.2 Preparation/Handling/Storage/Accountability ................................................. 42
6.2.1 Dose Preparation .......................................................................................... 42
6.2.2 Handling, Storage, and Accountability ........................................................ 42
6.3 Measures to Minimize Bias: Randomization and Blinding .............................. [ADDRESS_463891] to Follow -up................................................................................................ .47
8 STUDY ASSESSMENTS AND PROCEDURES ........................................................ 47
8.1 Administrative and General Procedures ........................................................... 48
8.1.1 Informed Consen t......................................................................................... 48
[IP_ADDRESS] General Informed Consent ................................................................ .48
[IP_ADDRESS] Consent and Collection of Specimens for Future Biomedical 
Research ............................................................................................. [ADDRESS_463892] .....................................................................49
8.1.4 Inclusion/Exclusion Criteria ........................................................................50
8.1.5 Medical History ........................................................................................... 50
8.1.6 Prior and Concomitant Medications Review ............................................... 50
[IP_ADDRESS] Prior Medications ............................................................................... 50
[IP_ADDRESS] Concomitant Medications ..................................................................[ADDRESS_463893] ............................................................................................. 50
8.1.8 Assignment of Treatment/Randomization Number .....................................51
08MVGC
08SK8Z
	
 

	

 	
		

 		
==D ,)$-)+/)!
 !!)+)!========================= ===================================== A
==D= ! !10#
 !!)+)!=========================== ============================== A
== .&*)+!***!)!:+)+27================ ============================== A
== #!*)!$)!H!)+?&=========================== ====================================== A
=== H!)+?&
+ 
$)$+'! !*&+*============= ===================A
== +)!*!:)'&!!1K%&!!1========================== ======================================== A
== &!%+)!0.C$!: )================================= ============================================ A
B< **)-'-(0////*-/  >9
== #1$!+$$*)!$)+&!")!)27========= ======================A
==
B8 10////*-/  >>
== -!*&.> !)!*&$!18!1)H!1)========= ======================== AA
== !)&,!1'- :+)$+($+ )============= ======================== AA
== )/**!)!,0)-%+/)!+!================= ================================ A<
== &!!*&,0)-%+)+-
 )==================== ================================= A<
==A 
 )0======================================== ============================================= A<
B9 .2&/2-/!&')/.2&/2-/!-.4&,'&+ 10
2-/  >;
== ! +!
+C$*-0+&&*)!1
.,
.) +
:+)%&,0)-./)0+ )!============================ ============================== A@
== ()0#)*)!1
.,
.)+:+)%&,0)- ./)======A
== 
&&?	$:0
.,
.)+:+)%&,0)-./) 0+ )!===AD
== 1$&)+-:+)!1C$!+ )0+,
.================= ============================ AD
==A +1*-.>:$+#$+!1'+)0!1=============== =========================== AD
==< #!	+&)./)K+#!	+&)$)* ) 3$&!0-!1

.+,
.================================================= =========================================== <
==@ ./)0&!!*&)+)=============================== ============================================= <
== 
/+./):+)).&*)+!***!)!: +)+=======<
=== ,&!*!)
/+./)================================ =================================== <
=== &!*!)
/+./)============================== ================================= <
B> 
&*-'12&.'/  ;:
B; 4&*('?-(/  ;:
B@ 4&*('.0-*(/  ;:
BB ))&5'*.(/&(4*,	'('-  ;<
BD 4('-'*(/.(/')&(E'--.4(' -'*(/;<
B:= A/6)&*-/  ;<
== ,*+!1================================================ ====================================================== <
== +) )+!K**!)!!!)======================= ===================================== <
09*&CCI
6.=
	
 

	

 	
		

 		
== #!*)!$+)!*!:))!$!1)%(!)+!) ,)$-========== <
D 


	  ;<
D: /(-0//-)**&0  ;8
D< /,'-/+01'&-0//
-34')/5-.-  ;9
D8 0,'4//
/*'-  ;>
D9 -0//-.,'-/  ;>
D==   $1!*!)- .:!)=================================== ==================<A
D== ,0)-.:!)========================================== ================================================ <A
D> -0//',)'-/  ;;
D=A=   $1!*!)-
&-!:$&)!======================= ================================= <<
D=A= ,0)-
&-!:$&)!=============================== ========================================= <@
D; /(4'./  ;@
D=<= ,))!)!*&()0+  $1!*!)-
&-=========== =========================== <@
D=<= ,))!)!*&()0+,0)-
&-=================== =================================== <
D=<= ,$  +!0'&!+*)+!)!*# 1+:!* )+

&-======================================================= ================================================ @
D@ -&*-0//  @:
DB ),(0  @:
DD *,E-.'F&	()'-/  @:
D=D= , :&,!"?+0+  $1!*!)-
&-========= ======================@
D=D= , :&,!"?+0+,0)-
&-================= ============================== @
D:= )+&'),-0//  @8
D:: 	'*,-($.('-.4&-(%  @8
D:< C-'1C,'/)&  @8
:= 
	



	
  @9
:=: ,,-.C:)'&0!4(!-.).02&/4	'-/. &'-/@9
== 0$*)0+&!!*&+!&====================== ======================================= @
== 
!*!&#!*&$+===================================== ================================================ @<
== #)+)*)!========================================== =================================================== @@
=== 0!)!&!)-0#)================================ ====================================== @@
=== 0!)!&!)-0+)!*!:)*+================= ============================== @@
=== 0!)!&!)-0'K.0+ )!================= =========================== @@
==   !)),)+$*)$+===================================== ============================================== @
=== .>*$)!//+!1)  !))========================== ============================== @
=== .>)+&#)(!)+!1  !))===================== ========================== @
==A $%&!*)!&!*-======================================== ================================================ @
==<  :&!*?!),)$-1!)+)!$&))!1 C$!+ )===@
09*&CCI
6.=
PRODUCT: V181  13
PROTOCOL/AMENDMENT NO.: 003-01
V181 -003-01FINAL PROTOCOL 14-JUL-2022
10.1.7 Compliance with Law, Audit, and Debarment ............................................ 79
10.1.8 Data Quality Assurance ............................................................................... 79
10.1.9 Source Documents ....................................................................................... 80
10.1.10 Study and Site Closure ................................................................................. 81
10.2 Appendix 2: Clinical Laboratory Tests .............................................................. 82
10.3 Appendix 3: Adverse Events: Definitions and Procedures for Recording, 
Evaluating, Follow -up, and Reporting ............................................................... 83
10.3.1 Definitions of Medication Error, Misuse, and Abuse ..................................83
10.3.2 Definition of AE .......................................................................................... 83
10.3.3 Definition of SAE ........................................................................................ 85
10.3.4 Additional Events Reported ......................................................................... 86
10.3.5 Recording AE and SAE ............................................................................... 86
10.3.6 Reporting of AEs, SAEs, and Other Reportable Safety Events t o the 
Sponsor ........................................................................................................92
10.4 Appendix 4: Device Events, Adverse Device Events, and Medical Device 
Incidents: Definitions, Collection, and Documentation ....................................94
10.5 Appendix 5: Contraceptive Guidance ................................................................ 95
10.5.1 Definitions ....................................................................................................95
10.5.2 Contraception Requirements ........................................................................96
10.6 Appendix 6: Collection and Management of Specimens for Future 
Biomedical Research ............................................................................................ 97
10.7 Appendix 7: Country -specific Requirements .................................................. 102
10.8 Appendix 8: Abbreviations ............................................................................... [ADDRESS_463894]: V181  14
PROTOCOL/AMENDMENT NO.: 003-[ADDRESS_463895] OF TABLES
Table 1 Study Interventions .......................................................................................... 41
Table 2 Reporting Time Periods and Time Frames for Adverse Events and Other 
Reportable Safety Events ................................................................................. 58
Table 3 Solicited Adverse Events for V181 -003.......................................................... 60
Table 4 Analysis Strategy for Immunogenicity Variables ............................................ 68
Table 5 Analysis Strategy for Safety Parameters .......................................................... 70
Table 6 Differences in Incidence of Adverse Event Rates Between the 2 
Vaccination Groups That Can be Detected With an ~80% Probability 
(Assuming a 2- Sided 5% Alpha Level With 230 Participants in the V181 
High Potency Level Group and 115 Participants in the Placebo Group) ........72
Table 7 Differences in Incidence of Adverse Event Rates Between the 2 
Vaccination Groups That Can be Detected With an ~80% Probability 
(Assuming a 2- Sided 5% Alpha Level With 460 Participants in the V181 
Mid Potency Level or V181 Low Potency Level Group and 115 
Participants in the Placebo Group) ..................................................................[ADDRESS_463896]: V181  15
PROTOCOL/AMENDMENT NO.: 003-[ADDRESS_463897]: V181  16
PROTOCOL/AMENDMENT NO.: 003-01
V181 -003-01FINAL PROTOCOL 14-JUL-2022
1 PROTOCOL SUMMARY
1.1 Syno psis
Protocol Title: A Phase 2, Randomized, Double -Blind, Multicenter Study to Evaluate the 
Safety and Immunogenicity of Three Different Potenc y Levels of V181 (Dengue 
Quadrivalent Vaccine rDENVÎ”30 [live, attenuated]) in Healthy Adults
Short Title: Safety and Immunogenicity of Three V181 Dengue Vaccine Potenc iesin Adults
Acronym: V181 -003
Hypotheses, Objec tives ,and Endpoints :
The following objectives and endpoints will be evaluated in healthy male and female 
participants, 18 to 50 years of age (inclusive).
Primary Objectives Primary Endpoints
-To compare the dengue virus -neutralizing 
antibody geometric mean titers (GMTs) for 
each of the 4 dengue serotypes at Day 28 
postvaccination for participants administered 
the V181 Low Potency Level versus V181 
Mid Potency Level
Hypothesis: V181 Low Potency Level is 
non-inferior to V181 Mid Potency Level for 
each of the 4 dengue serotypes based on 
GMTs at Day 28 postvaccination.
(The statistical criterion for non -inferiority 
requires the lower bound of the 2 -sided 95% 
CI of the GMT ratio [V181 Low Potency 
Level versus V181 Mid Potency Level] be 
great er than 0.67 for each dengue serotype)-Dengue virus -neutralizing antibody titers 
for each of the [ADDRESS_463898] (VRNT)
-To evaluate the safety and tolerability of [ADDRESS_463899]: V181  17
PROTOCOL/AMENDMENT NO.: 003-[ADDRESS_463900] to 
the proportion of participants experiencing 
solicited AEs-Solicited injection -site adverse events from 
Day 1 through Day 5 postvaccination
-Solicited systemic adverse events from Day 
1 through Day 28 postvaccination
Overall D esign:
Study Phase Phase [ADDRESS_463901] 
participant (or their legally acceptable representative) 
provides documented informed consent until the last 
participant's last study -related contact.
For purposes of analysis and reporting, the overall study 
ends when the Sponsor receives the last laboratory result 
or at the time of final contact [CONTACT_26355], 
whichever comes last.
08MVGC
08SK8Z
	
 

	

 	
		

 		
)*+&'1&(,-/

::+>! )&-<A:+)!*!:)?!&&%+ !"!)!)$- =
-&2-'-&'),/-.)&'-
)+/)!
J+$:
&**-&2-'-
*-'/&-4
$%')'1
.*-A((-
*- /
8!1
)*-/&
J+$:8!1
)*-/&,,!1&)
!!)2#-7)
+$*)
(!
)*-/&
J+$:(!
)*-/&,,!1&)
!!)2#-7)
+$*)
?
)*-/&
J+$:?
)*-/&,,!1&)
!!)2#-7)
+$*)
&*%J+$: &*%  ,,!1&)
!!)2#-7&*%

 !=Q !!)+)!R
Q)::&!*%&R
Q:&C$0+ !1 $!)R,Q$%*$)$
!+:+))0!&)+1)0*+)-:0+ =A 00)+0!&:+:+)!
:+):+ *- $&=
)&
$ %+0)+/)!J+$:K
+ !)+/)!1+$:
#$+)!0
+)!*!:)!.*:+)!*!:)?!&&:+)!*!:)!))$-0+::+>! )& - )
0+ ))! ):+)!*!:):+/!*$ )!0+ * )
)+$1)0!&*)*)=
09*&CCI
6.=
PRODUCT: V181  19
PROTOCOL/AMENDMENT NO.: 003-01
V181 -003-01FINAL PROTOCOL 14-JUL-2022
Study Governance Committees:
Steering Committee No
Executive Oversight Committee Yes
Data Monitoring Committee Yes
Clinical Adjudication Committee No
Study governance considerations are outlined in Appendix 1.
Study Accepts Healthy Volunteers :Yes
A list of abbreviations used in this document can be found in Appendix 8.
08MVGC
08SK8Z
PRODUCT: V181  20
PROTOCOL/AMENDMENT NO.: 003-[ADDRESS_463902]: V181  21
PROTOCOL/AMENDMENT NO.: 003-01
V181 -003-01FINAL PROTOCOL 14-JUL-2022
1.3 Schedule of Activities
Study Period:Screening /
Randomization /
InterventionFollow -up
(through Month 12 postvaccination)Notes
Visit Number/Title: 1 2 3 4 5 6 7 8
Scheduled Day or 
Month :Day [ADDRESS_463903] TC.Visit Window Permitted :Pre-
DoseDosePost-
DoseÂ±2 days
(Days 5 
to 9)Â±2 days
(Days 10 
to 14)+14 days
(Days 2 8
to 42)Â±14 days
(Days 76 
to 104)Â±14 days
(Days 166 
to 194)Â±14 days
(Days 256 
to 284)Â±14 days
(Days 346 
to 374)
Administrative Procedures
Informed Consent XConsent must be 
obtained BEFORE any 
study procedures, 
including screening.
Informed Consent for 
FBRXParticipation in FBR is 
optional. C onsent must 
be obtained before 
collection of FBR 
samples.
Assignment of Screening 
NumberX
Participant Identification 
CardX
Inclusion/Exclusion 
CriteriaX
Medical History XIncludes medical 
history for 5 years 
before screening .
Prior/Concomitant 
Medication /Vaccines 
ReviewX X X X X X X XAfter Visit 4, report only 
concomitant medications
associated with SAEs
and/or receipt of
investigational or 
approved dengue 
vaccine. Section s 5.[ADDRESS_463904]: V181  22
PROTOCOL/AMENDMENT NO.: 003-01
V181 -003-01FINAL PROTOCOL 14-JUL-2022
Study Period:Screening /
Randomization /
InterventionFollow -up
(through Month 12 postvaccination)Notes
Visit Number/Title: 1 2 3 4 5 6 7 8
Scheduled Day or 
Month :Day [ADDRESS_463905] TC.Visit Window Permitted :Pre-
DoseDosePost-
DoseÂ±2 days
(Days 5 
to 9)Â±2 days
(Days 10 
to 14)+14 days
(Days 2 8
to 42)Â±14 days
(Days 76 
to 104)Â±14 days
(Days 166 
to 194)Â±14 days
(Days 256 
to 284)Â±14 days
(Days 346 
to 374)
Urine Pregnancy Test 
(WOCBP only)XPerformed by [CONTACT_3725] .
WOCBP must have 
negative result before
vaccination.
Serum hCG 
(WOCBP only)XSerum hCG is tested 
only if the urine 
pregnancy test is 
inconclusive. WOCBP 
must have negative 
result before 
vaccination .
Randomization/Vaccination
Assignment of 
Randomization NumberX
V181/Placebo 
AdministrationXOnly b linded study 
personnel administer 
study vaccine /placebo . 
See Section 8. 1.9.
Distribute eVRC XStudy-s ite personnel 
will train participant on
useof eVRC.
Immunogenicity Procedures
Serum samples for 
Dengue Antibody Titers 
(VRNT)X X X X Xï‚·Day [ADDRESS_463906] be collected 
before vaccination. 
See Section 8.2.
ï‚·For half of 
participants in each of 
the [ADDRESS_463907]: V181  23
PROTOCOL/AMENDMENT NO.: 003-01
V181 -003-01FINAL PROTOCOL 14-JUL-2022
Study Period:Screening /
Randomization /
InterventionFollow -up
(through Month 12 postvaccination)Notes
Visit Number/Title: 1 2 3 4 5 6 7 8
Scheduled Day or 
Month :Day [ADDRESS_463908] TC.Visit Window Permitted :Pre-
DoseDosePost-
DoseÂ±2 days
(Days 5 
to 9)Â±2 days
(Days 10 
to 14)+14 days
(Days 2 8
to 42)Â±14 days
(Days 76 
to 104)Â±14 days
(Days 166 
to 194)Â±14 days
(Days 256 
to 284)Â±14 days
(Days 346 
to 374)
Safety Procedures
Full Physical 
Examination Including 
Height and WeightXFull physical 
exam ination is required 
to determine study 
eligibility. See Section 
8.3.1.
Vital Signs X See Section 8.3.2.
Postvaccination Safety 
ObservationXBlinded study personnel 
monitor participant at 
the study site for at least 
30 min for any 
immediate reactions
following vaccination . 
See Section 8.3.3.
AE/SAE Review X X X X X X X Xï‚·After Visit 4, only 
MAAEs, SAEs , and 
deaths are reported.
ï‚·Rashes with onset D1 
to D28 
postvaccination 
should be evaluated 
by [CONTACT_249305] 72 hrs of onset 
(Section 8.3.5) .
Review of eVRC X X XReview the eVRC with 
the participant at Visits 
2, 3, and 4.
Collect Electronic 
Device for eVRCXFor participants who 
received a study -
supplied device.
08MVGC
08SK8Z
	
 

	

 	
		

 		
,)$-+!B,*+!1K
 !")!K
)+/)!
&&?	$:
2)+$1():)/**!)!7)
!!)$ %+K!)&B     A < @ 
,*$&#-+
()B#- #-@ #- #- () ()<()D
()
+!!)A&00
:+)!*!:)!*1+$:?!&&/
0+!!)<)+&0
?!&&/= !!)H!?+ !))B+	
##)	
#T-
2#-A
)D7T-
2#-
)7P-
2#-
)7T-
2#-@<
)7T-
2#-<<
)D7T-
2#-A<
)7T-
2#-<
)@7
5'*&?&/
'&2#
70+
' I&&*)%0+
/**!)!0+ 
+ !"
'	*):+)!*!:)&-=
'&0+)!1II+ $)%)&)
-%)?!!)!!)=

.Q/+/)RJQ$ *+!!*1)+:!R#
Q>-+ !%$*&!**!RQ&*)+!*/**!)!+:+)*+R
'Q0 $)$+%! !*&++*R(

.Q
 !*&&-))/+/)R,
.Q+!$/+/)R Q)&:*)*)RQ/!+$+$*)!$)+&!")!))RH 'Q? 0*!&	 %+!1:))!&
09*&CCI
6.=
	
 A

	

 	
		

 		
< 
	

(,#!/&:!11$C$+!/&)/**!+#.42&!/ ))$)7+0)+
+0++)!*&&%+)!?!))!)$)'$))0 +):+/)!01$
!!!!/!$&)+!90>:$+%-&!/!1!+)+/ &!1)1$	 !*+=
!&9?#1$
!:+*&!!*&) $!=
<: ).0'-	)$-!!1))0)-!  $1!*!) -0:)*-&/&0
=')*&!!*&0)-!  $1!*!)-)0+ )!) $-?!&&:+/!%))+
$+)!10)*&!!*&:+0+ *0)/**!*+ ?!+10:)*!
$::+)))%&! )0:)*-+&:*!0!*)!0+ )/**!=)$-
/**!:)*-&/&!)!)$-+)!&! %&=)+1):)*-0 
K+)-:%)%&!!*&!!*&)$!*$*) %-)8
*&!!*&)$!*$*)%-(,#)8)!)$)'$) )=+)!*!:)?!&&%
+ !"!BBB+)!))8!1)*-/&J+ $:(!)*-
/&J+$:?)*-/&J+$::&*%=
:+! +-:!)0))$-!%!  $1!*!)-? !*?!&&%/&$)!
)U:$+)V0!!:+)!*!:)?+1$	+1)!/ )%&!:+	
>!)!1!  $!)-)1$+)-:K)$1 ))!   $+:))+
+)-:!0&$*)+$&)=:+)!*!:)1+1 0)A-+?&*)
!++)!*&$&)-$&)?!)!)*)!  $-) * :%&0:)! &!  $
+:!)!)$-))!*&$-:)!	+!/:+!  +-!  $1!*!)-%L*)!/=
#!00+*+)>:*)!!  $1!*!)-%-1$%1+$: ?!)!)!)$-
::$&)!=
<< 5(?&')-.0+))'0+)!&%*91+$!0+ )!8 1$

'$))	#=
<<: -)//-.A:B:2',*-#1$! 1) )! :+))+)+:	%+/!+&! !)+ 0$ 
 +%!!)- +)&!)-!)?+&5H+&8&)+1!")! D65J$" (=J=)
&65
+W='=)&@65++==)+ =@65J$" (=J=)
&65H!)+=
+++=658&),='= @65:!	-+=)&
D65,$-=
=)&D6=
::+>! )&-)%!&&!:: &&!/!1!)+:!*&
$%)+:!*&*$)+!+)	+!90+!0*)!=.*-+::+ >! )&-D !&&!::&
+!0*)?!)1$/!+$*$!1)! )D< !&&! - :) )!**5'))
,=)&6=0)= !&&!*+/++$&)! 1!::+>! )&-
)5 ,==.-==6=
$+)+ +::+> ! )&- !&&!::&
)+/&)1$	 !*+1!$&&-5,$-=
=)& D6=+0+)+!
&+1$ ) !*&0+1$/**!=
09*&CCI
6.=
PRODUCT: V181  26
PROTOCOL/AMENDMENT NO.: 003-01
V181 -003-01FINAL PROTOCOL 14-JUL-2022
Dengue disease is caused by 4 virus serotypes : DENV1, DENV2, DENV3, and DENV4 .
Infection by [CONTACT_39780] [ADDRESS_463909] that 
serotype . Infection with one serotype may provide short -term protection ( ie, 6to 24 months) 
against other serotypes, but does not provide long- term protection. Secondary infections with 
a different viral serotype increase the risk for development of severe disease forms (ie, DHF
and DSS )and death. I t has been hypothesized that the increase in severity with secondary 
infection may be immune -mediated through a mechanism termed ADE [Halstead, S. B. 
2007] [Halstea d, S. B. 2014] [Guzman, M. G., et al 2013] .According to this hypothesis , 
nonneutralizing, cross -reactive, heterotypic antibodies bind to a heterologous infecting 
serotype and facilitate uptake of the virus into Fc receptor -bearing target cells (such as
monocytes and macrophages), leading to increased viral replication and higher viral and 
viral-antigen NS1 loads that trigger cytokine release that ultimately mediates the plasma 
leakage syndrome observed in DHF. Given this natural history, ADE represents a theoretical 
risk for any dengue vaccine. This risk is considered to be inversely related to efficacy (eg, 
risks in partic ipants where vaccine is not effective or efficacy wanes) [Cassetti, M. C. 2014] .
Study participants will be informed in the ICF of the potential risk of ADE after vaccination 
with V181 and ways to protect themselves from exposure to mosquitos if they travel to 
dengue endemic areas.
Based on the above ADE hypothesis , the foremost approach for developi[INVESTIGATOR_370780] -induced sensitivity for more severe disease 
is a 4- valent vaccine that will simultaneously and durably protect against disease caused by 
[CONTACT_21129] 4 dengue virus serotypes [Halstead, S. B. and Deen, J. 2002] .
V181 is comprised of the attenuated viral strains rDEN V1Î”30, rDEN V2/4Î”30(ME), 
rDENV3Î”30/31, and rDEN V4Î”30 and is intended toprevent disease caused by [CONTACT_210696] 4 
dengue sero types (DENV1, DENV2, DENV3, and DENV4). The parental viruses for V181 
wereinitially developed by[CONTACT_370788] -licensed by [CONTACT_1034] . Attenuation of all 4 viral 
components in NIH dengue LATV was achieved by [INVESTIGATOR_119991] (eg, deletion of 30 
nucleotides in the 3â€™ non- coding region ( âˆ†30) of the dengue genome. DENV2 is the only 
serotype that is not a full -length homotypic genome, but is instead a chimeric virus with the 
prM and E protein from DENV2 inserted into an attenuated DENV4 backbone. In addition, 
DENV3 also has an additional 31- nucleotide deletion in the 3 non -coding region ( âˆ†30/31). 
The vaccine viral strains are referred to as rDENV1 âˆ†30, rDENV2/4âˆ†30(ME), 
rDENV3 âˆ†30/31, and rDENV4âˆ†[ADDRESS_463910]: V181  27
PROTOCOL/AMENDMENT NO.: 003-[ADDRESS_463911] been performed on the components of the NIH dengue LATV 
admixture , which supports the V181 clinical program given that the vaccines are similar in 
design. Preclinical information for the NIH dengue LATV is provided in the IB .
2.2.3 Completed Clinical Studies
A brief summary of completed clinical studies are provided below, and details are provided 
in the IB.
[IP_ADDRESS] MSD V181 Completed Studies
Results from the V181 -001 Phase 1 study indicated V181 ishighly immunogenic through 
6months postdose 1 and generally safe and well tolerated in flavivirus -naÃ¯ve and flavivirus-
experienced participants. AEs were generally assessed as mild to moderate in intensity by [CONTACT_32346] .
[IP_ADDRESS] NIH Dengue LATV Completed Studies
To date ,the NIH has administered the dengue LATV monovalent components or tetravalent 
formulations comprising the same parental strains as V181 to more than 1000 participants 
with studies ongoing in the US andThailand. The NIH monovalent and tetravalent vaccines 
were generally well -tolerated in both nonclinical and human studies conducted by [CONTACT_941] N IH.
[IP_ADDRESS] Butantan -DVClinical Studi es
V181 and Butantan- DVare derived from the same parental strains originally developed by 
[CONTACT_18121], are produced using similar methods, have the same antigenic composition and are 
therefore fundamentally the same .Therefore , data from Butantan clinical tri als are relevant 
for V181.
Butantan- DV wasevaluated in a Phase 2 study of 300 participant s (of which 210 received 
Butantan- DV) in Brazil. The vaccine wasfound to be immunogenic and generally safe and 
well-tolerated in both dengue -naÃ¯ve and dengue -exposed participants [Kallas, E. G., et al 
2020] . The vaccine is currently being investigated in a large Phase 3 safety and efficacy 
study with approximately 17,000 participants enrolled in Brazil.
2.2.4 Information on Other Study -related Therapy
Not applicable.
2.3 Benefit/Risk Asse ssment
It cannot be guaranteed that participants will directly benefit from study vaccination duri ng 
participation, since this clinical study is being conducted to evaluate the safety and 
immunogenicity of an investigational dengue vaccine.
08MVGC
08SK8Z
PRODUCT: V181  28
PROTOCOL/AMENDMENT NO.: 003-01
V181 -003-01FINAL PROTOCOL 14-JUL-2022
Data generated to date in V181, NIH dengue LATV, and Butantan- DV clinical studies 
demonstrated that these vaccines are generally safe, well tolerated, and highly immunogenic. 
The frequency, severity, and magnitude of the AEs identified in these studies support a 
favorable benefit -risk analysis for the dengue vaccine in the study population.
Additional details regarding specific benefits and risks for the participants in this clinical 
study may be found in the accompanying IB and informed consent documents.
3 HYPOTHESE S, OBJECTIVES ,AND ENDPOINTS
The following objectives and endpoints will be evaluated in healthy male and female 
participants, 18 to 50 years of age (inclusive).
Objectives Endpoints
Primary
â€¢To compare the dengue virus-
neutralizing antibody geometric mean 
titers (GMTs) for each of the 4 dengue 
serotypes at Day 28 postvaccination for 
participants administered the V181 Low
Potency Level versus V181 Mid Potency 
Level
Hypothesis: V1 81Low Potency Level is
non-inferior to V181 Mid Potency Level
for each of the 4 dengue serotypes based 
on GMTs at Day 28 postvaccination.
(The statistical criterion for non-
inferiority requires the lower bound of 
the 2- sided 95% CI of the GMT ratio 
[V181 Low Potency Level versus V181 
Mid Potency Level ] be greater than 0.67 
for each dengue serotype)â€¢Dengue virus -neutralizing antibody 
titers for each of the [ADDRESS_463912] (VRNT )
â€¢To evaluate the safety and tolerability of 
[ADDRESS_463913] to the proportion of participants 
experiencing SAEsï‚·Vaccine -related serious adverse events 
from Day 1 through Day 28 
postvaccination
08MVGC
08SK8Z
	
 D

	

 	
		

 		
%L*)!/ .:!)
,*+-
Z/&$))0)-)&+%!&!)-0
!00+):)*-&/&?!)+:*))):+:+)!0:+)!*!:)>:+!*!1&!*!)
.Z,&!*!)!L*)!	!)/+/)0+ #-)+$1#-A:)/**!)!
Z,&!*!)-) !*/+/)0+ 
#-)+$1#-:)/**!)!
+)!+-K.>:&+)+-
09*&CCI
6.=
PRODUCT: V181  30
PROTOCOL/AMENDMENT NO.: 003-01
V181 -003-01FINAL PROTOCOL 14-JUL-2022
4 S TUDY DESIGN
4.1 Overall Design
This is a double -blind with in -house blinding, randomized, placebo -controlled, multicenter , 
study to evaluate the safety and immunogenicity of 3 different potenc y levels of V181, 
compared with placebo, in healthy adults 18 to 50 years of age .The study will be conducted 
in dengue non- endemic regions. Approximately 1265 participants will be randomized 2: 4:4:1
to receive a single dose of 1 of 3 potency levels (high, mid, or low) of V181 or placebo. The 
duration of the study for each participant will be approximately [ADDRESS_463914] or unblinded qualified study site personnel at each site will be
required to manage clinical supplies and prepare the study vaccine/placebo in order to 
maintain the blinding of the clinical material and the study. Once the study vaccine /placebo
has been prepare d, it willbe provided to a blinded member of the study team for 
administration to the participant. Th eparticipant, the investigator, and Sponsor personnel or 
delegate(s) involved in the study intervention administration or clinical evaluation of the 
participants will be blinded to the intervention assignments.
Participants will be screened to document general good health on Day 1 . When deemed 
eligible for study participation, participants will be randomized and vaccinated with 1 of 3 
different potency levels of V181 or placebo on the same day (Day 1) .
A standardized eVRC will be distributed to all participants for the collection of the following 
data on a daily basis beginning with the day of vaccination (Day 1) through Day 28
postvaccination:
ï‚·Solicited injection- site AEs of injection- site pain, injection -site erythema, an d injection-
site swelling from Day 1 through Day 5 postvaccination
ï‚·Solicited systemic AEs of rash, headache, fatigue (tiredness), myalgia (muscle pain), and 
arthralgia (joint pain )from Day 1 through Day 28 postvaccination
ï‚·Unsolicited AEs from Day 1 through Day 28 postvaccination
ï‚·Oral temperatures from Day 1 through Day 28 postvaccination
ï‚·Concomitant medications and nonstudy vaccines from Day [ADDRESS_463915] thei r own electronic 
device configured, if compatible, to complete the eVRC. Study -supplied devices will be 
collected on Day 28.
08MVGC
08SK8Z
	
 

	

 	
		

 		
,&!*!)
.&!)%/$&!*!)
.2!*&$!1(

. ,
.7?!&&%
*&&*)#-)+$1#-=
&&?!1#-:)/**!)! (

.,
.
2+1+&0*$&!)-7)2$)-*$7?!&&% *&&*))+$1()
:)/**!)!=
+)!*!:)0)-?!&&% !)+%-#())?!&&:+0 + :+!!*+/!?00)-
))+$1$)))$-2
::!>7=#)!&?!&&%:+/! !)#(*+)+=
'& :&0+) )0!  $+:?!&&%* &&*)0+ &&:+)!*!:)
%0+/**!)!#-))#-():)/ **!)!)! :!)=
+)!*!:)!*)+) )1+$:?!&&%+ !"!* )+&!":+*))&0
0):+)!*!:)!*1+$:/%& :&*&&*) )()))+&0
)()<=+)!*!:)?+)*$&)/%&+? :+)!+!1
*$&?!&&/)&:/!!)=
)!)$-?!&&%* $*)!	 !*
*$)+!!)!>:*))))%&!+))$0+)  L+!)-0:+)!*!:)?!&&%
1$	+1)!/=+0+*+!10+1$+))$ ?!&&)%*$*)=
0!&)+ !)!0%&!+))$0+):$+:0) :+! +-&-!?!&&%%-
)=
!)!)0)-!  $1!*!)- )%& : &0+ ))!1?!&&
%%)!))#-@#-:)/**!)!)! :!)=
,+$  :&0+ %))!  $1!*!)- %&+??!&& *%
&!C$)!)$%=)$%?!&&%!::):+:*!0! *)+&&%+)+-)$%
?!&&+ !))!)%*9	$: :&!*) !  :&!)+-!-?-=
,:+?!&&)!0-)!)?)%*9	$: :&*% !::))&%+)+-=
0+))/)!1)+,)$-
!&'!+0+1$!*+1+! 1 :&%&/&$ 
)+&%+)+-:+*$+=
:+! +-0)-!  $1!*!)-&-?!&&%*$*) ))#-
:)/**!)!)! :!))$::+)))%&! )0) :)*-+&:*!0!*)!
0+=
,?!&&%?+!))):+)))$-+$&)0+  )!)! :+!=
  $1!*!)-0)-+$&)0+ )#-)+$1() :)/**!)!)! 
:+!?!&&%$  +!"!0!&:+))$-+:+)2 ,*)!D=7=
,:*!0!*:+*$+)%:+0+ $+!1))$-!*&$!1 :+*+!%)! 
*!)/!!)?!?+$)&!!,*)!==#)!& 0*:+*$++:+/!
!,*)!=
9< (-1('-1'&).0/-
!)$-!!1))!  $+:0+:+)! *!:))A-+01
0&&?!1/**!)!?!)!1&00:)*-&/ &0=8!1(!
2)+1)7?)*-/&))?!&&% !!)++ )!&!%&=')
*&!!*&0)-!  $1!*!)-)0+ )!)$-?!&&$ ::+)))%&! )0
:)*-+&:*!0!*)!0+=
+):+! +-!  $1 !*!)-%L*)!/
09*&CCI
CCI
6.=
PRODUCT: V181  32
PROTOCOL/AMENDMENT NO.: 003-01
V181 -003-01FINAL PROTOCOL 14-JUL-2022
postvaccination immune responses will be assessed for participants to con firm that the 
immune response for the V181 Low P otency Level falls within a predetermined ratio in 
comparison to the V181 Mid (target) P otency L evel.The V181 High Potency Level will 
provide an assessment of the safety of V181 at a potency level that is higher than the Mid 
(target) Potency Level .
4.2.1 Rationale for Endpoints
[IP_ADDRESS] Immunogenicity Endpoints
A single dose of 1 of 3 potency levels of V181 will be assessed for postvaccination 
neutralizing antibody responses to the 4 vaccine virus serotypes at Day 28 postvaccination 
using thevalidated VRNT assay. Specimens for the primary endpoints for immunogenicity 
testing will be obtained from the entire study population (N= 1265) at Day 28 .
The time point of Day 28 was chosen as the primary endpoint based on the immunogenicity 
results observed in the V181- 001 study. Among flavivirus -naÃ¯ve participants, the observed 
seropositivity rates ranged from 70.6% to 97.1% for each of the 4 dengue serotyp es. The 
percentage of these flavivirus- naÃ¯ve participants who achieved quadrivalent or trivalent 
responses was 85.3%. In addition to the evaluation for all participants at Day 28, antibody 
responses will be evaluated for half of the participants in each group at Month 3 and the other 
halfat Month 6, and for all participants at Month 12 postvaccination time point sin order to 
assess the durability of immune responses.
The above immunogenicity schedule was designed to evaluate the phen omenon of a 3- phase 
immune response in seronegative participants to natural infection or live vaccines . 
Specifically, this refers to (1) a rapid increase in titer (over about 1 month) ; (2) a rapid decay 
after that peak (over another month );and then (3) a slower decay to a new equilibrium [Alter, 
G. 2020] . Based on these immune kinetics, an alternating immunogenicity visit design is 
planned in order to evaluate immunogenicity at multiple timepoints while minimizing the 
number of blood draws per participant [Food and Drug Administration 2019] . Ateach of the 
Month 3and M onth 6visits, half of the participants will have blood draws for 
immunogenicity. Those participants who are assigned for blood draws at Month [ADDRESS_463916] 
telephone calls at Month 6; likewise participants who are assigned to have telephone calls at 
their Month [ADDRESS_463917] blood draws at t heir Month 6 visit. The resulting schema will 
provide immunogenicity data at 4 separate postvaccination time points (Day 28, M onth 3, 
Month 6, and M onth 12), while only requiring 3 postvaccination blood draws per participant.
As noted above, because the pr imary endpoint of the study is based on immunogenicity, the 
study will be conducted in participants who are dengue -seronegative at baseline, so a pre -
existing immunity to a dengue serotype/s does not augment the immune response to other 
serotypes and influence the results. A participant is classified as dengue -seronegative if 
VRN T is negati ve for all four dengue serotypes.
TheVRNT is a high -throughput virus neutralization assay, specific for each of the 4dengue 
serotypes. Serum samples are first diluted and incubated with virus to allow for antibody 
08MVGC
08SK8Z
	
 

	

 	
		

 		
%!!1/!+$$)+&!")!=+$ /!+$ !>)$+! )!*$%)
?!)+*&&)&&?0+!0*)!%-	$)+&!"/!+$= $ %+0!!/!$&
!0*)*&&!)*)*$)%-/!+$!  $)!!1 %0+:&C$0+ )!=
$&)+>:+$)+&!"!1!)+=H!&*++&) 0:+)*)!%
)%&!0+1$) $+ )0/!+$	$)+&!"!1 )!%-+::+/!
 *! ))!  $1!*!)-0)/**!$!10$ *)!&-)) -
:+!*)):))!&0+:+)*)!=
9<:< 10-.,'-/:+! +-0)-/&$)!:+!0+)!)$-!#-) +$1#-:)/**!)!=
	-:+! +-0)-0&&?	$::+!?&*)% )0)-)0+ )
	*&!!*&)$-)*&!!*&)$!0+) 8
=

?!&&%!)+!%$))&&:+)!*!:)!++)*&& *):+)!*!:)	+:+)/)
!&-%!0+ )-0/**!)!2#-7)+$1# -:)/**!)!=
!/&!))&+$)!&-$0+0)-$+/!&&* !/**!*&!!*&)$!
*$*)%-),:+?:+/!$&-$!)	 *&!!*&)$-=

&&?!1#-:)/**!)!,
.?!&&%*&&*))+$1 ():)/**!)!
0+* :+!//&$)!00)-0+)$+)!0) )+!&=
#)!&)0)-:!)/&$)!)!)$-+:+ /!!,*)!=
,*)!D===#)!&
.!*&$!10!!)!+:+)! 1+C$!+ )+:+/!
!,*)!=2
::!>7=
9<:8 4&C,'&'&0-.,'-/
9<:9 ))&5'*.(/&(4
,:+?!&&*$*)0$)$+%! !*&++*:*!  0+?!**)?
:+/!$+!1)!)$-=!++* -!*&$1)!* &-2#
71
>:+!:+0!&!12
7:+) !* )%& !*2+$ :&  7K+)
09*&CCI
6.=
	
 

	

 	
		

 		
 $+ )0)+&-):!1?!*:*! + *)0+0$)$+
%! !*&++*=
,$*++*!0+%! +9+))!1)+ +1)C$ )!)*+!%&?+
!):+)*&2:+)0) !)$-7?!&&&-%* $*):*! 0+ 
::+:+!)&-*):+)!*!:)=%L*)!/0*&&*)! 1K+)!!1:*! 0+
0$)$+%! !*&++*!)>:&+!)!0-%! +9+ ))!0+ )*!)!0!*
$+)!10!K+)!+)+:$)!*)+) )= /++*!11&!)$
$*!0+ )!)/&:0+ +00*)!/+$1K/**! K+)$+))
:+)!*!:)+*!/)*++*)0)*++*)+$1K/**! ))*++*))! =
)!&00$)$+%! !*&++*+:+)!
::!> <=
9<< '-1'&4/'1	'*,&'&
(+'&*%2$):+:+!&$)!0)8!1)*-/ &(!)*-
/&))?)*-/&7?!&&% !!)++  0)!)$-2QA
:+)!*!:)7!++):++/)%&!!1:+/!* )+&0+)0)- )
0)*)!/)$-/**!+ =
!)!&&-))$-!%! 1*$*)!	 !*
*$)+!?+)+!&?+!901$!0*)!/**! )!?!)&!*1$
/**!27!)+$)!&-*$*)=
98 #)/1('-1'&'/
!1&00:)*-&/&0+:&*%?!&&%  !!)+
$%*$)$&-#-!)!)$-=$&)0+ ) )$-2	7
 )+)))**:)%&0)-:+0!&! !  $1!*)):)*-
&/&0 0+*/**!* :)2!)U !V:)*-&/&$+/&$)!!)!)$-7=?)+:)*!2! U!1VU&?V&/&
:)*!7?!&&%/&$)!)!)$-!++)%))+$ +))*&!!*&
:+0+ *0)/**!*+?!+10:)*! )$::+)))%&! )
0:)*-+&:*!0!*)!0+2 %&7=H!&)0)-
!  $1!*!)-0?!&&%/&$)*+&&0): )*-&/&):+! +-
!  $1!*!)-:!)0*$!  $1!*!)-0) &?+:)*-* :+
?!)))!$*)))+1):)*-&/&)9-*+!)+ !)%=
99 5----.-.3'13).01-'-/+&&)$-%1!?)0!+):+)!*!:)2+)!+& 1&&-**:)%&+:+))!/7
:+/!*$ )!0+ *)=/+&&)$-? )&):+)!*!:)
* :&))&))$-	+&)*)*)?!)+?*)+ !&))0&&?	$:2!)
:+)!*!:)!$%&)%*)*)%-)!/)!1)+7=

+:$+:0&-!+:+)!1)/+&&)$- ?),:++*!/)
&)&%+)+-+$&)+)))! 00!&*)*)?!)) &):+)!*!:)?!*/+* 
&)=
09*&CCI
6.=
PRODUCT: V181  35
PROTOCOL/AMENDMENT NO.: 003-01
V181 -003-01FINAL PROTOCOL 14-JUL-2022
4.4.1 Clinical Criteria f orEarly Study Termination
The clinical study may be terminated early if the extent (incidence and/or severity) of 
emerging effects/clinical endpoints is such that the risk/benefit ratio to the study population 
as a whole is unacceptable. In addition, further recruitment in the study or at (a)particular 
study site(s) may be stopped due t o insufficient compliance with the protocol, GCP, and/or 
other applicable regulatory requirements, procedure -related problems or the number of 
discontinuations for administrative reasons is too high .
[ADDRESS_463918] for Cl inical Trials (Appendix 1), this study includes 
participants of varying age (as applicable) , race, ethnicity, and sex (as applicable) . The 
collection and use of these demographic data will follow all local laws, participant 
confidentiality guidelines while supporting the study of the disease, its related factors, and 
the IMP under investigation.
Healthy male and female participants between the ages of 18 and 50 years (inclusive) will be 
enrolled in this study.
Prospective approval of protocol deviations to recruitment and enrollment criteria, also 
known as protocol waivers or exemptions, is not permitted.
5.1 Inclusion Criteria
A participant is eligible for inclusion in the study if the participant :
Type of Participant and Disease Characteristics
1.Is healthy based on review of medical history and physical examination ,according to the 
clinical judgement of the investigator.
Demographics
2.Ismale or female , from 18years to 50years of age inclusive, at the time of signing the 
informed consent.
Participants Assigned Male Sex at Birth
3.Male participants are eligible to participate if they agree to the following for at least 90 
days after administration of study intervention (a spermatogenesis cycle is approximately 
90 days) :
â€¢Abstains from heterosexual intercourse as their preferred and usual lifestyle (abstinent 
on a long term and persistent basis) and agree to remain abstinent
OR
08MVGC
08SK8Z
PRODUCT: V181  36
PROTOCOL/AMENDMENT NO.: 003-01
V181 -003-01FINAL PROTOCOL 14-JUL-2022
â€¢Must agree to use contraception unless confirmed to be azoospermic (vasectomized 
or secondary to medical cause [Appendix 5] )as detailed below :
- A gree to use a male condom plus partner use of an additional contraceptive 
method when having penile -vaginal intercourse with a WOCBP who is not 
currently pregnant. Note: Men with a pregnant or breastfeeding partner must 
agree to remai n abstinent from penile -vaginal intercourse or use a male condom 
during each epi[INVESTIGATOR_19329] -vaginal penetration .
â€¢Contraceptive use by [CONTACT_370789] .
Female Participants
4.A female participant is eligible to participate ifnotpregnant or breastfeeding, and at least 
one of the following conditions applies:
â€¢Is not a WOCBP
OR
â€¢Is a WOCBP and using a contraceptive method that is highly effective (with a failure 
rate of <1% per year), or be abstinent from heterosexual intercourse as their preferred 
and usual lifestyle (abstinent on a long term and persistent basis), as described in 
Appendix [ADDRESS_463919] 90 days after administration of study intervention. The 
investigator should evaluate the potential for contraceptive method failure (ie, 
noncompliance, recently initiated) in relationship to the first dose of study 
intervention.
â€¢A WOCBP must have a negative highly sensitive pregnancy test (uri ne or serum as 
required by [CONTACT_427]) before the first dose of study intervention.
â€¢If a urine test cannot be confirmed as negative (eg, an ambiguous result), a serum 
pregnancy test is required. In such cases, the participant must be excluded from 
participation if the serum pregnancy result is positive.
â€¢The investigator is responsible for review of medical history, menstrual history, and 
recent sexual activity to decrease the risk for inclusion of a woman with an early 
undetected pregnancy.
â€¢Contraceptive use by [CONTACT_42282].
08MVGC
08SK8Z
PRODUCT: V181  37
PROTOCOL/AMENDMENT NO.: 003-01
V181 -003-01FINAL PROTOCOL 14-JUL-2022
Informed Consent
5.The participant (or legally acceptable representative) has provide d documented informed 
consent for the study. The participant may also provide consent for Future Biomedical 
Research. However, the participant may participate in the main study without 
participating in Future B iomedical Research.
5.[ADDRESS_463920] be excluded from the study if the participant:
(If a participant meets any of the exclusion criteria marked with an asterisk (*), the Day 1 
visit may be rescheduled for a time when these criteria are no longer met , as long as the study 
is still open to enrollment .)
Medical Conditions
1.Has known history of dengue or zika natural infection .
2.*Has an acute febrile illness (temperature â‰¥38.0Â°C [â‰¥100.4Â°F] oral or equivalent) 
occurring within 72 hours before receipt of study vaccine /placebo .
3.Has a serious or progressive disease according to the investigator, including but not 
limited to cancer ;uncontrolled diabetes; severe cardiac, renal, or hepatic insufficiency; or 
systemic autoimmune or neurologic disorder.
4.Has known or suspected impairment of immunological function , including but not limited 
to congenital or acquired immunodeficiency, HIV infection, hematologic malignancy, or 
treatment for autoimmu ne disease s.
5. Has a condition in which repeated venipuncture or injections pose more than minimal 
risk for the participant, such as hemophilia, thromboc ytopenia, other severe coagulation 
disorders, or significantly impaired venous access .
6.Has a known hypersensitivity to any component of the study vaccine /placebo , or history 
of severe allergic reaction (e g, swelling of the mouth and throat, difficulty brea thing, 
hypotension or shock) that required medical intervention .
Prior/Concomitant Therapy
7.Has received a dose of any dengue vaccine (investigational or approved) before study 
entry , orplans to receive any dengue vaccine (investigational or approved) for the 
duration of the trial .
08MVGC
08SK8Z
PRODUCT: V181  38
PROTOCOL/AMENDMENT NO.: 003-01
V181 -003-01FINAL PROTOCOL 14-JUL-2022
8.*Has received other licensed non- live vaccines within 14 days before receipt of study 
vaccine /placebo or is scheduled to receive any licensed non -live vaccine within 28days 
following receipt of study vaccine /placebo .Exception: Inactivated influenza vaccine may 
be administered but must be given at least 7 days before receipt of study vaccine /placebo
or at least 28 days after receipt of study vaccine /placebo .
9.*Has received a licensed live vaccine within 28 days before receipt of study 
vaccine /placebo or is scheduled to receive any live vaccine within 28days after receipt of 
study vaccine /placebo .
10.Has received systemic corticosteroids (equivalent of â‰¥2 mg/kg /day of prednisone or 
â‰¥20mg/d for persons weighing >10 kg) for â‰¥[ADDRESS_463921] 30 days before study entry or is expected to r eceive systemic 
corticosteroids at aforementioned dose and duration within 28 days after receipt of study 
vaccine /placebo . (Note: Topi[INVESTIGATOR_370781]/ne bulized steroids are permitted.)
11.Has received systemic corticosteroids exceeding physiologic replacement doses 
(approximately 5 mg/d ayprednisone equivalent) within 14 days before vaccination.
12.Has received immunosuppressive therap ies, includ ingchemotherap eutic agents used to 
treat cancer or other conditions, treatments associated with organ or bone marrow 
transplantation, or autoimmune disease , within 6 months before receipt of study 
vaccine /placebo or plans to receive immunosuppressive therapi[INVESTIGATOR_6523] 28 days after 
receipt of study vaccine /placebo .
13.Has received a blood transfusion or blood products (including immunoglobulins) within 6 
months before receipt of a study vaccine /placebo or plans to receive a blood transfusion 
or blood products (including immunoglobulins) within 28 days after receipt of study 
vaccine /placebo .
Prior/Concurrent Clinical Study Experience
14.Has participated in another clinical study of an investigational product within 6 months 
before signing the informed consent, or plans to participate in another interventional 
clinical study at any time during the duration of the current clinical study. Pa rticipants 
enrolled in observational studies may be included; these will be reviewed on a case -by-
case basis for approval by [CONTACT_1034].
Diagnostic Assessments
Not applicable.
08MVGC
08SK8Z
PRODUCT: V181  39
PROTOCOL/AMENDMENT NO.: 003-01
V181 -003-01FINAL PROTOCOL 14-JUL-2022
Other Exclusions
15.Has any other reason that, in the opi[INVESTIGATOR_871], may interfere with the 
evaluation required by [CONTACT_1758] .Reasons may include, but are not limited to, being 
unable to complete the eVRC, being unable to complete visits including non -office visit 
contacts (eg, telephone), or being unable to comply with study procedures.
16.Has planned donation of blood, eggs, or sperm at any time from signing the informed 
consent through 90 days postvaccination.
17.Is or has an immediate family member (eg, spouse, parent/legal guardian, sibling, or 
child) who is investigationa l site or Sponsor staff directly involved with this study .
5.3 Lifestyle Considerations
No lifestyle restrictions are required for this study.
5.4 Screen Failures
Screen failures are defined as participants who consent to participate in the clinical study, but 
are not subsequently randomized in the study. A minimal set of screen failure information is 
required to ensure transparent reporting of screen failure participants to meet the CONSORT 
publishing requirements and to respond to queries from regulatory authorities. Minimal 
information includes demography, screen failure details, eligibility criteria, and any AEs or 
SAEs meeting reporting requirements as outlined in the data entry guidelines.
5.5 Participant Replacement Strategy
A participant who withdraws from t he study will not be replaced.
6 STUDY INTERVENTION
Study intervention is defined as any investigational intervention(s), marketed product(s), 
placebo, or me dical device(s) intended to be administered to a study participant according to 
the study protocol .
Clinical supplie s provided by [CONTACT_151519] .Clinical 
supplies will be affixed with a clinical label in accordance with regulatory requirement s.
V181 study vaccine will be prepared by [CONTACT_370790] , as described in 
Section 6.2.1; therefore, clinical supplies will be open- label in this study. The open- label 
clinical supplies will be distributed to unblinded study personnel at the clinical site and 
prepared by [CONTACT_370791], a s per the 
instructions in the Investigator Study File Binder, which includes the Pharmacy Manual ,
provided by [CONTACT_1034] .There is no visual difference between the V181 potency level study 
vaccine and placebo in the syringe. O nce study vaccine /placebo has been prepared, it willbe 
provided to a blinded member of the study team for administration to the participant.
08MVGC
08SK8Z
PRODUCT: V181  40
PROTOCOL/AMENDMENT NO.: 003-01
V181 -003-01FINAL PROTOCOL 14-JUL-2022
6.1 Study Intervention(s) Administered
The study intervention(s) to be used in this study are outlined inTable 1 .
08MVGC
08SK8Z
	
 

	

 	
		

 		
%& ,)$-)+/)!
&*
* &*
0,-&2-'
-*-&2-'-

0,'/
'&*)'--'/&-4$/%
$%'/
2$/%')'1
.*-3
/&'-*-

&*-
&'.
A((-'-
*- /'&

C')&(-

8!1)*-
/&
J+$:.>:+! )& 8!1
)*-/&'!&1!*&K
**!,)+!&,&$)! =A  , ,!1&)
!!))
+$*)(,:+

(!
)*-/&
J+$:.>:+! )& (!
)*-
/&'!&1!*&K
**!,)+!&,&$)! =A  , ,!1&)
!!))
+$*)( ,:+

?)*-
/&
J+$:.>:+! )& ?
)*-/&'!&1!*&K
**!,)+!&,&$)! =A  , ,!1&)
!!))
+$*)( ,:+
&*%
J+$:&*%
 :+)+&*% '!&1!*&K
**!,)+!&,&$)!  =A  , ,!1&)
!!)&*% ( ,:+

>(Q$>!&!+- !*!&:+$*)R#.Q1$/!+$R..
Q.$+ :.* !*
+R(Q!/)!1)!& !*!&:+$*)R (Q	!/)!1)!& !*!&:+$*)R
Q:&C$
0+ !1$!)R,Q$%*$)$
*&!0!*)!0 ((K
>(!%1$!*!$ %-).$+:  !!::&!)*$)+!!).. 
=$)+-!00+*?!)+:*)))
0!!)!K*&!0!*)!0( (K
>( ->!)=)*!+*$ )*&*&&1!&)!!0 &&?=
!+:+))0!&)+1)0*+)-:0+ =A 00)+0!&:+:+)!:+):+ * - $&=
09*&CCI
6.=
	
 

	

 	
		

 		

&&$::&!!!*)! %&?!&&%:+/!:+)U,$+*!1V*&$ :!1
&*&*$)+-:+)!&+C$!+ )=0&*&$+*!1/+ -)) :)$&% )
$+*)$::&!0+ !1&&)K%)*$ %+?+: !%&21)::&!*%&!)
*?+ $&)!:&&)+%)* -%+C$!+$)) &1)0))$-)*7=
0+),*)!==D0+)!&+1+!1 !!)+)!0) )$-!)+/)!=
;< &,&'-
-.-
'&
((')-+0;<: '/&,&'-)$-/**!K:&*%?!&&%:+:+%-)$%&!:+  *!)+$%&!
C$&!0!)$-!):+&*+!%!,*)!< %&**+!1))
0&&?!1:+*$+B
8!1)*-/&)$-/**!?!&&%:+:+%-+ *)!)$)!1)8!1
)*-/&/**!/!&:+/!%-),:+?!)?)+0+ !L*)!)
0!& !>!12!&$)!17?!):&*%)+*)::+:+!): )*-&/&=
(!)*-/&)$-/**!?!&&%:+/!%-) ,:+))
!):)*-0 ?!&&&-+C$!++*)!)$)!?!) 
?)+0+!L*)!%0+ !!)+)!=
?)*-&/&)$-/**!?!&&%:+:+%-+* )!)$)!1)
(!)*-/&)$-/**!?!)?)+0+!L*)!) 0!& !>!12!&$)!17
?!):&*%)+*)&?+:)*-=
:&*%!$::&!!&!C$!0+ )+C$!++* )!)$)!=
#)!&0+):+:+)!0))$-/**!K:&*%+:+/ !!)+ *-
($&:+/!%-),:+=
;<< -.-!'&!-.((')-+0!/)!1)++!1 $)*0!+ ::+:+!)) :+)$ +*!)!/%
 !)!$+!1)+!)0+&&)$-!)+/)!+*!/ -!*+:*!+
+:+)+&/%0+$0))$-!)+/)!=
&-:+)!*!:)+&&!))$- -+*!/)$-!)+ /)!&-$)+!"
!))00 -$::&-+ !!)+)$-!)+/)!=
&&)$ -!)+/)! $)%)+
!*$+/!+ )&&-*)+&& !)+2 $& +$) )7+!
**+*?!))&%&)+1*!)!?!)**&! ! )))!/)!1)+
$)+!"!))00=
!/)!1)+!)!)$)!+)0) !*&!)!) $)!2?+::&!*%&7!
+:!%&0+)$-!)+/)!**$)%!&!)-+**!&!)! +*+ !)*2!
+*!:)+**!&!)!0!&!:!)!+*+7=
09*&CCI
6.=
PRODUCT:   V181  43
PROTOCOL/AMENDMENT NO.:   [ADDRESS_463922]/destruction procedure is 
documented.
The study site is responsible for recording the lot number, manufacturer, and expi[INVESTIGATOR_19333] (if applicable) as per local guidelines unless otherwise 
instructed by [CONTACT_1034].
The investigator shall take responsibility for and shall take all steps to maintain appropriate 
records and ensure appropriate supply, storage, handling, distribution, and usage of study 
interventions in accordance with the protocol and any applicable laws a nd regulations.
6.3 Measures to Minimize Bias: Randomization and Blinding
6.3.1 Intervention Assignment
Intervention randomization will occur centrally using an IRT system. There are 4study 
intervention arms. Participants will be assigned randomly in a 2:4:4:1ratio to the V181 High 
Potency Level Group, V181 Mid Potency Level Group, V181 Low Potency Level Group, 
and placebo .
6.3.2 Stratification
No stratification based on age, sex, or other characteristics wil l be used in this study.
6.3.3 Blinding
Adouble -blinding technique with in- house blinding will be used . V181 study vaccine 
(3potency levels )and placebo will be provided open -label .Therefore, an unblinded 
pharmacist or unblinded qualified study site personnel will be responsible for receiving, 
maintaining, and preparing the study vaccine /placebo in accordance with a Pharmacy Manual 
provided by [CONTACT_1034]. An unblinded Clinical Research Associate will monitor vaccine 
accountability at the study site.
Once the study vaccine /placebo has been prepare dby [CONTACT_370792] , the study vaccine /placebo willbe provided to a blinded 
member of the study tea m for administration to the participant. To avoid bias, contact 
[CONTACT_370793]. Additionally, blinded site personnel will not be present when the study 
vaccine /placebo is prepared. Blinded study -site personnel will be responsible for all safety 
follow -up,and blinded study- site personnel will be responsible for immunogenicity specimen 
collection before/ after study vaccine /placebo administration. Laboratory personnel 
responsi ble for conducting the assays will remain blinded to vaccination group assignments 
throughout the duration of the study.
08MVGC
08SK8Z
PRODUCT:   V181  44
PROTOCOL/AMENDMENT NO.:   003 -01  
V181 -003-01FINAL PROTOCOL 14-JUL-2022
The participant, investigator, and study- site personnel directly involved in the clinical 
evaluation of the participants, a s well as Sponsor field personnel or delegate(s) involved with 
the conduct of this study will be blinded to the participant -level intervention assignments.
An unblinded statistician and statistical programmer not directly involved in the conduct of 
the study will b e responsible for providing unblinded report deliverables to the eDMC. 
Details will be provided in the eDMC charter .
Following Day [ADDRESS_463923] of the trial will be unblinded to vaccination g roup assignments for the primary safety 
and immunogenicity analyses . The primary CSR will be authored to present the results from 
Day 1 through Day 28 to support the establishment of the potency release specifications for 
V181 .A blinded medical monitoring team will monitor the study after Day 28 through 
Month 12 postvaccination.
Investigators ,study site personnel , participants, and Sponsor field personnel or delegate(s )
will remain blinded to treatment group assignments until the final study analyses are 
completed following the Month 12 (final) database lock.
See Section 8.1.[ADDRESS_463924] with the study vaccine, as well as all other potentially contaminated materials, will be 
collected in dedicated containers and will be destroyed in a safe manner. This study will be 
conducted under local country regulations fo r use of a GMO.
6.6 Concomitant Therapy
The following medications/vaccinations are prohibited before and/or during the study:
ï‚·Any dengue vaccine (investigational or approved) before study entry, or plans to receive 
any dengue vaccine (investigational or approved) for the duration of the trial
ï‚·Any licensed non -live vaccine 14 days before receipt of study vaccine /placebo or is 
scheduled to receive any licensed non -live vaccine within [ADDRESS_463925]:   V181  45
PROTOCOL/AMENDMENT NO.:   003 -01  
V181 -003-01FINAL PROTOCOL 14-JUL-2022
vaccine /placebo . Inacti vated influenza vaccine may be administered but must be given at 
least 7 days before or 28 days after receipt of study vaccine /placebo .
ï‚·Any licensed live vaccine within 28 days before or after receipt of study vaccine /placebo.
ï‚·Systemic corticosteroids (equ ivalent of â‰¥2 mg/kg/day of prednisone or â‰¥20 mg/day for 
persons weighing > 10 kg) for â‰¥[ADDRESS_463926] 30 days before study entry or is expected to receive systemic corticosteroids at 
aforementioned doses and du ration within 28 days after receipt of study vaccine /placebo
(topi[INVESTIGATOR_370781]/nebulized steroids are permitted).
ï‚·Has received systemic corticosteroids exceeding physiologic replacement doses 
(approximately 5 mg/day prednisone equivalent) within 14 days before vaccination.
ï‚·Has received immunosuppressive therapi[INVESTIGATOR_014], including chemotherapeutic agents used to 
treat cancer or other conditions, treatments associated with organ or bone marrow 
transplantation, or autoimmune disease, within 6 months before receipt of study 
vaccine /placebo or plans to receive immunosuppressive therapi[INVESTIGATOR_6523] 28 days after 
receipt of study vaccine /placebo .
ï‚·Has received a blood transfusion or blood products (including immunoglobulins) within 6 
months before receipt of a study vaccine /placebo or plans to receive a blood transfusion 
or blood products (including immunoglobulins) within 28 days after receipt of study 
vaccine /placebo .
The final decision on any supportive therapy or vaccination rests with the investigator and/or 
the participantâ€™s primary physician. However, the decision to continue the participant in the 
study requires the mutual agreement of the investigator, the Sponsor, and the participant.
Any medication or vaccine (including over -the-counter or prescription medic ines, vitamins, 
and/or herbal supplements or other specific categories of interest) that the participant is 
receiving at the time of enrollment or receives from the time of vaccination through Day [ADDRESS_463927] be recorded along with:
â€¢ Reason fo r use
â€¢Dates of administration including start and end dates
â€¢Dosage information including dose and frequency
After Day 28 postvaccination (Visit 4), only concomitant medications associated with SAEs 
should be reported. The Clinical Director should be contact[CONTACT_51013].
08MVGC
08SK8Z
PRODUCT:   V181  46
PROTOCOL/AMENDMENT NO.:   003 -01  
V181 -003-01FINAL PROTOCOL 14-JUL-2022
6.6.1 Rescue Medications and Supportive Care
No rescue or supportive medications are specified for use in this study.
6.7 Dose Modification
No dose modification is allowed in this study.
6.7.1 Stoppi[INVESTIGATOR_370782].
6.8 Intervention After the End of the Study
There is no study -specified intervention following the end of the study.
6.9 Clinical Supplies Disclosure
This study is blinded but supplies are provided as open label ; therefore, an unblinded 
pharmacist or qualified study site personnel will be used to blind supplies. Study intervention
identity (name, strength, or potency) is included in the label text; rand om code/disclosure 
envelopes or lists are not provided.
The emergency unblinding call center will use the intervention/randomization schedule for 
the study to unblind participants and to unmask study intervention identity. The emergency 
unblinding call cen ter should only be used in cases of emergency (see Section 8.1.1 2). Ifthe 
emergency unblinding call center is not available for a given site in this study, the central 
electronic intervention randomization system (IRT) should be used to unblind participants 
and to unmask study intervention identity. The Sponsor will not provide random 
code/disclosure envelopes or lists with the clinical supplies.
See Section 8.1.[ADDRESS_463928]:   V181  47
PROTOCOL/AMENDMENT NO.:   [ADDRESS_463929] be withdrawn from the study if the participant or participantâ€™s legally 
acceptable representative withdraws consent from the study.
If a participant withdraws from the study, they will no longer be followed at scheduled 
protocol visits.
Specific details regarding procedu res to be performed at the time of withdrawal from the 
study, as well as specific det ails regarding withdrawal from future biomedical r esearch, are 
outlined in Section 8.1.11. The procedures to be performed should a participant repeatedly 
fail to return for scheduled visits and/or if the study site is unable to contact [CONTACT_63517] 7.3.
7.[ADDRESS_463930] t o Follow -up
If a participant fails to return to the clinic for a required study visit and/or if the site is unable 
to contact [CONTACT_2299], the following procedures are to be performed:
â€¢The site must attempt to contact [CONTACT_19423]. If the 
participant is contact[INVESTIGATOR_530], the participant should be counseled on the importance of 
maintaining the protocol -specified visit schedule.
â€¢The investigator or designee must make every effort to regain contact [CONTACT_19424] (eg, telephone calls and/or a certified letter to the participantâ€™s last 
known mailing address or locally equivalent m ethods). These contact [CONTACT_19425]â€™s medical record.
â€¢Note: A participant is not considered lost to follow -up until the last scheduled visit for the 
individual participant. The missing data for the participant will be ma naged via the 
prespecified statistical data handling and analysis guidelines .
8 STUDY ASSESSMENTS AND PROCEDURES
â€¢Study procedures and their timing are summarized in the SoA.
â€¢Adherence to the study design requirements, including those specified in the SoA, i s 
essential and required for study conduct.
â€¢The investigator is responsible for ensuring that procedures are conducted by 
[CONTACT_19426] (by [CONTACT_8640], training, and experience) staff. Delegation of 
study-site personnel responsibilities will be do cumented in the Investigator Trial File 
Binder (or equivalent).
08MVGC
08SK8Z
PRODUCT:   V181  48
PROTOCOL/AMENDMENT NO.:   003 -01  
V181 -003-01FINAL PROTOCOL 14-JUL-2022
â€¢All study- related medica l decisions must be made by [CONTACT_19427] a qualified 
physician.
â€¢All screening evaluations must be completed and reviewed to confirm that potential 
participant s meet all eligibility criteria. The investigator will maintain a screening log to 
record details of all participants screened and to confirm eligibility or record reasons for 
screening failure, as applicable.
â€¢Procedures conducted as part of the participantâ€™s routine clinical management (eg, blood 
count) and obtained before signing of ICF may be used for screening or baseline purposes 
provided the procedure met the protocol -specified criteria and were performed within the 
time frame defined in the SoA.
â€¢Additional evaluations/testing may be deemed necessary by [CONTACT_88686]. In some cases, such evaluation/testing 
may be potentially sensitive in nature (eg, HIV, hepatitis C), and thus local regulations 
may require that additional informed consent be obtained from the participant. In these 
cases, such evaluations/testing will be performed in accordance with those regulations.
The approximate total maximu m amount of blood volume drawn from each participant is 
50mL, as detailed in the Investigator Study File Binder .
Repeat or unscheduled samples may be taken for safety reasons or for technical issues with 
the samples.
8.1 Administrative and General Procedures
8.1.1 Informed Consent
The investigator or medically qualified designee (consistent with local requirements) must 
obtain documented informed consent from each potential participant (or their legally 
acceptable representative) before participating in t his clinical study or FBR. If there are 
changes to the participantâ€™s status during the study (eg, health or age of majority 
requirements), the investigator or medically qualified designee must ensure the appropriate 
documented informed consent is in place .
[IP_ADDRESS] General Informed Consent
Informed consent given by [CONTACT_19429] a consent form. The form must include the study protocol number, study 
protocol title, dated signature, and agreement of the participant (or his/her legally acceptable 
representative) and of the person conducting the consent discussion.
A copy of the signed and dated informed consent form should be given to the participant (or 
their legally acceptable representative) before pa rticipation in the study.
08MVGC
08SK8Z
PRODUCT:   V181  49
PROTOCOL/AMENDMENT NO.:   [ADDRESS_463931] receive the IRB/IECâ€™s approval/favorable opi[INVESTIGATOR_19349]. The 
participant or his/her legally acceptable representa tive should be informed in a timely manner 
if new information becomes available that may be relevant to the participantâ€™s willingness to 
continue participation in the study. The communication of this information will be provided 
and documented via a revise d consent form or addendum to the original consent form that 
captures the participantâ€™s or the participantâ€™s legally acceptable representativeâ€™s dated 
signature.
Specifics about the study and the study population are to be included in the study informed 
consent form.
Informed consent will adhere to IRB/IEC requirements, applicable laws and regulations, and 
Sponsor requirements.
[IP_ADDRESS] Consent and Collection of Specimens for Future Biomedical Research
The investigator or medically qualified designee will explain th e FBR consent to the 
participant, or the participantâ€™s legally acceptable representative, answer all of his/her 
questions, and obtain documented informed consent before performing any procedure related 
to FBR. A copy of the informed consent will be given to the participant before performing 
any procedure related to FBR .
8.1.[ADDRESS_463932] not be re -used for 
different participants.
Any participant who is screened multiple times will retain the original screening number 
assigned at the initial Screening V isit. Specific details on the screening/rescreening visit 
requirements are provided in Section 8.10.1.
8.1.[ADDRESS_463933] information (including direct 
telephone numbers) to be used in the event of an emergency. The investigator or qualified 
designee will provide the participant with a participant identification card immediatel y after 
the participant provides documented informed consent. At the time of intervention 
randomization, site personnel will add the treatment/randomization number to the participant 
identification card.
08MVGC
08SK8Z
PRODUCT:   V181  50
PROTOCOL/AMENDMENT NO.:   [ADDRESS_463934] information for the emergency 
unblinding call center so that a healthcare provider can obtain information about study 
intervention in emergency situations where the investigator is not available.
8.1.4 Inclusion/Exclusion Criteria
Before randomization, a ll inclusion and exclusion criteria will be reviewed by [CONTACT_1275] ,who is a qualified physician, to ensure that the participant qualifies for the 
study.
8.1.5 Medical History
A medical history will be obtained by [CONTACT_370794]. The participantâ€™s 
relevant medical history for the 5 years before Visit 1 (Day 1) will be obtained to ensure that 
the participant satisfies the inclusion and exclusion criteria of the study.
8.1.6 Prior and Concomitant Medications Revi ew
[IP_ADDRESS] Prior Medi cations
The investigator or qualified designee will review prior medication /vaccination useand 
record prior medication s/vaccinations taken by [CONTACT_78772] 30 days before 
enrolling in the study in order to assess the study inclusion and exclusion criteria, including 
time windows for medication/vaccination use .
[IP_ADDRESS] Concomitant Medications
At Visit 1 (Day 1) and at Visits 2, 3, and [ADDRESS_463935] medication s and nonstudy vaccines , if any, t aken by [CONTACT_370795] 28 postvaccination.
In addition, the participant will use their e VRC ( Section 8.1.10) to record new and/or 
concomitant medications and nonstudy vaccines received from Day 1 through Day 28 
postvaccination.
After D ay 28 postvaccination , only concomitant medications related to SAEs are reported.
Receipt of any dengue vaccine (investigational or approved) other than study 
vaccine /placebo must also be reported.
8.1.[ADDRESS_463936] consistent with local requirements (which must be sensitive to detect hCG 
at concentrations of 25 IU/L) must be performed in WOCBP at screening or within [ADDRESS_463937] dose of study vaccine /placebo is administered as described in Section 1.3. 
Urine or serum tests may be used, and results must be negative before study vaccine /placebo
is administered. If a urine pregnancy test cannot be confirmed as negative (eg, an ambiguous 
result), a serum pregnancy test is requir ed. A negative urine or serum Î²-hCG pregnancy test 
08MVGC
08SK8Z
PRODUCT:   V181  51
PROTOCOL/AMENDMENT NO.:   [ADDRESS_463938] be documented on the day of vaccination before administration of study 
vaccine/placebo. A detailed definition of WOCBP is provided in Appendix 5.Additional 
pregnancy tests may be performed at the discretion of the investigator or as required by [CONTACT_370796].
8.1.8 Assignment of Treatment/Randomization Numb er
All eligible participants will be randomly allocated and will receive a 
treatment /randomization number. The treatment /randomization number identifies the 
participant for all procedures occurring after treatment randomization. Once a 
treatment /randomization number is assigned to a participant, it can never be reassigned to 
another participant.
A single participant cannot b e assigned more than 1 treatment /randomization number.
8.1.9 Study Intervention Administrati on
Study vaccine/placebo should be prepared and administered by [CONTACT_370797] (eg, physician, nurse, physicianâ€™s assistant, nurse
practitioner, pharmacist, or medical assistant) as allowed by [CONTACT_5737]/state, country, and 
institutional guidance.
Study intervention is given on the day of treatment allocation/randomization or as close as 
possible to the date on which the participant is al located/assigned.
Unblinded study personnel not otherwise involved in the conduct of the study will prepare 
study vaccine /placebo . Unblinded study personnel should not have contact [CONTACT_20688].
Once the study vaccine /placebo has been prepare d by [CONTACT_370792] , the study vaccine /placebo willbe provided to a blinded 
member of the study team for administration to the participant . All safety and 
immunogenicity assessments wi ll be conducted by [CONTACT_229191], and the participant will 
be blinded to the study vaccine /placebo received.
Details of each vaccination should be documented on the appropriate eCRF as specified in 
the data entry guidelines . Procedures for handling, preparing, and administering, disposing 
of, and returning the unblinded vaccines are provided in the Investigator Study File Binder, 
which includes the Pharmacy Manual .
[IP_ADDRESS] Timing of Dose Administration
In this study, V181 or placebo will be administ ered as a 0.5- mL subcutaneous injection at 
Visit 1 (Day 1). The day of the study vaccination is considered Day [ADDRESS_463939] 30 minutes 
following each vaccination for any im mediate AEs; the time period can be extended if 
clinically indicated.
08MVGC
08SK8Z
PRODUCT:   V181  52
PROTOCOL/AMENDMENT NO.:   [ADDRESS_463940] (eVRC)
The eVRC was developed to be administered electronically via a hand -held device and is 
used to record AEs during the postvaccination period, as defined in Section 8.4. 8. The eVRC 
isstructured as recommended in the final US FDA Patient -Reported Outcome Guidance
[U.S. Department of Health and Human Services 2009].
Participants will be provided an electronic device or have their own electronic device 
configured, if compatible, to complete the eVRC. The participant will be trained by [CONTACT_370798] 
1 (Day 1). Noncompliance with the eVRC will require retraining by [CONTACT_370799].
Daily oral temperatures, injection -site reactions, other complaints or illnesses, and 
concomitant m edications/nonstudy vaccines will be recorded on the eVRC from Day 1 
through Day 28 postvaccination (see Section 4.1). Participants will be required to measure 
temperature using a digital thermometer provided by [CONTACT_370800]-
site r eactions of swelling and redness using a ruler provided by [CONTACT_1034]. Refer to Section 
8.4.8 for safety assessments using the eVRC.
For the specific AEs collected via the eVRC, the investigator or delegate will discuss 
information entered into the eVRC w ith the participant at Day 7, Day 12, and Day 28 
postvaccination (V isit 2, Visit 3, and V isit 4)and apply the appropriate assessment of overall 
intensity grade, as described in Appendix 3.
Any differences between eVRC data and the clinical database must b e documented in the 
participantâ€™s source record.
8.1.11 Discontinuation and Withdrawal
Participants in this study will receive a single dose intervention and cannot discontinue study 
intervention.
Participants who withdraw from the study should be encouraged to c omplete all applicable 
activities scheduled for the final study visit at the time of withdrawal. Any AEs that are 
present at the time of withdrawal should be followed in accordance with the safety 
requirements outlined in Section 8.4.
[IP_ADDRESS] Withdrawal From Future Biomedical Resear ch
Participants may withdraw their consent for future biomedical r esearch. Participants may 
withdraw consent at any time by [CONTACT_111954]. If medical 
records for the main study are still available, the investigator will contact [CONTACT_111955] (clinical.specimen.management@ MSD .com). Subsequently, the 
participant's consent for future biomedical r esearch will be withdrawn. A letter will be sent 
from the Sponsor to th e investigator confirming the withdrawal. It is the responsibility of the 
08MVGC
08SK8Z
PRODUCT:   V181  53
PROTOCOL/AMENDMENT NO.:   [ADDRESS_463941] is received.
In the event that the medical records for the main study are no longer available (eg, if t he 
investigator is no longer required by [CONTACT_180631]) 
or the specimens have been completely anonymized, there will no longer be a link between 
the participantâ€™s personal information and their specimens. In this s ituation, the request for 
specimen withdrawal cannot be processed.
8.1.12 Participant Blinding/Unblindi ng
STUDY INTERVENTION IDENTIFICATION INFORMATION IS TO BE UNMASKED 
ONLY IF NECESSARY FOR THE WELFARE OF THE PARTICIPANT. EVERY 
EFFORT SHOULD BE MADE NOT TO UNBL IND.
For emergency situations where the investigator or medically qualified designee (consistent 
with local requirements) needs to identify the intervention used by a participant and/or the 
dosage administered , he/she will contact [CONTACT_88693] a request for emergency unblinding. As requested by [CONTACT_19445], the emergency unblinding call center will provide the information to 
him/her promptly and report unblinding to the Spons or. Before contact[CONTACT_88694] a participantâ€™s intervention assignment, the 
investigator who is a qualified physician should make reasonable attempts to enter the 
intensity grade of the AEs observed, the relation to study intervention, the reason thereof , 
etc., in the medical chart. If it is not possible to record this assessment in the medical record
before the unblinding, the unblinding should not be delayed.
Ifunblinding has occurred, the circumstance s around the unblinding (eg, date, reason, and 
person performing the unblinding) must be documented promptly, and the Sponsor Clinical 
Director notified as soon as possible.
Once an emergency unblinding has taken place, the investigator, site personnel, an d Sponsor 
personnel may be unblinded so that the appropriate follow -up medical care can be provided 
to the participant.
Participants whose treatment assignment has been unblinded by [CONTACT_93311]/or nonstudy treating physician should continue to be monitored in the 
study.
Additionally, the investigator or medically qualified designee must go into the IRT system 
and perform the unblind in the IRT system to update drug disposition. In the event that the 
emergency unblinding call center is not available for a given site in this study, the IRT 
system should be used for emergency unblinding in the event that this is required for 
participant safety.
08MVGC
08SK8Z
	
 A

	

 	
		

 		
B::8 	+&'-'16),*-
!/)!1)++C$&!0!!1)+:!%!&!)-) $+))-/!*+
!)+$ )$0+*&!!*&/&$)!K))$+!1*&!!* &)$-)):+/!!0+ )!
%$)!*&$!K>*&$!*+!)+!K+0)-+00!**-: + )+&&%$!)%&-
*&!%+)K+ !)!)$+))))%)!+ +&!%&K++:+$*!%&=
#*$ ))!0C$!: )*&!%+)! $)%+)!$+ **$ ))!))
)$-!)=
B< **)-'-(0////*-/B<: -)A&)/.)('-)&E'-
/$A
%?!&&%*$*))$)+&!"!1)!%!0 +*0)1$
/**!+)-:2#.#.#.#.7!:*! *& &*)0+ 
/**!):+)!*!:)%0+/**!)!#-2%&!7 ))#-()
()<():)/**!)!)! :!)=
0+&&1$+)-:?/&!))3,&$)! *)+*)++*
+1!")!2,$:!)+
7=!:+0+ %- )?	0&+!&
!&$)!0+$  :&:!)!/*)+&!)!0 C$&/&$ 0!&$)
1$/!+$2#.#.#.+#.7*)!!1*! )))+1) $)
0/!+$0+*1!/+)-:
=!+$*)+&*)!!1!&$)/!+$?!)$)+$  :&
!&))=
0)+!*$%)!:+!)&&?0+/!+$ $)+&!")!*+$ K/!+$
 !>)$+/!+$*)+&!)+0++))!$*$&)$+:& )*)!!1*0&$)+
*&&!*$%))&&?0+	$)+&!"/!+$+:)! =
&&?!1+:)!)
!0*)*&&+!*$%)0+:*!0!:+!0)! ) &&?0++:&!*)!0)/!+$=
&)+0!>!0*)!!)*)%-!  $)!!1$ !1:*!0!*)!	1$
+%%!))!%-*+-)!%-&%&&?!)
&>
&$ +=)!)+0
 :&!)+ !%-*$)!1* :+!1)$ %+0! 0*)*&&!):+*
0)))+$ ))/!+$*)+&=+$&)++:+) $)+&!")!)!)+?!*
!)+*!:+*&0)!&$)!))+$*)$ %+0! 0*)*&&%-<N* :+)
)/!+$*)+&=&*$&)!+:+0+ $!1	:+ ) +&!+&1!)!*C$)!=
#1$+))$?!&&%)+ !%)<32 )!)++$&)[3+
*!+1)!/7*++:!1)*1$+)-: )%&!$+!1-
/&!)!=
09*&CCI
6.=
	
 AA

	

 	
		

 		
B8 10////*-/
B8: 40/(C*-'-/-().-4-."4
:+)0)*+!1:+*$+* :&):-!*&> ! )!?!&&%*$*)%-
!/)!1)++ !*&&-C$&!0!!12*!))?!) &*&+C$!+ )7:+
!)!)$)!&)+)!!)2#-7=

* :&):-!*&> !)!!*&$%$)!)&! !)) ) )0/!)&!1
2+)+)+:!+)+-+))%&:+$++& ) :+)$+7!1)?!1)
+)&$1% ?&&-+ )+)28..79!&- :
$+&1!*&-)  $*$&9&)&-) =/)!1 )+$&:-:*!&
)))!)*&!!*&!1+&)):+/!$+!$!&& =
)$+**$ )!/)!1)+$&*$ ):-!*& > !)!))
))$0&&*)!/ !*&*!)!=
-*&!!*&&-!1!0! *)%+ &!)-$&%
+*+)::+:+!)
=
B8< A-/-.5'.0
*,&)&/)&*-/!)&!1%-) :+)$++*+!1+:+)0):- !*&> !)!)!!)
2#-7!*&$B
Z'-) :+)$++)+)+:!+)+-+))%& :+$+=
Z'&:+$++)+) $+ )?!&&%0) +):+)!*!:))
&)A !$)0+)!C$!)))!1?!)$)!)+*)! 0+ !))!1:!)!
?!)* :&)&-$) )/!*=($&)*!C$?!&&%$ &-!0
$) )/!*!)/!&%&=

%+ &/!)&!1 $)%*0!+ %-+:)))!10)+ A !$)=
!!1+&)
))/!)&!1$&%*$ )!):+)!*!:)$+ **$ ))!=
-
*&!!*&&-!1!0!*)%+ &!)-?!&&%+*+)::+ :+!)
=
09*&CCI
6.=
PRODUCT:   V181  56
PROTOCOL/AMENDMENT NO.:   003 -01  
V181 -003-01FINAL PROTOCOL 14-JUL-2022
Oral temperatures will be recorded by [CONTACT_370801] 1 through 
Day 28 postvaccination.
For this study, any temperature â‰¥100.4Â°F (â‰¥38.0Â°C) oral or oral equivalent will be considered 
an AE of fever. All fevers must be reported Day [ADDRESS_463942] be recorded on the appropriate eCRFs .
8.3.4 Clinical Safety Laboratory Assessments
No clinical safety laboratory assessments are planned for this study .
8.3.5 Assessment of Rash
Rash is a solicited systemic AE and participants who experience rash during the primary 
postvaccination safety period (Day 1 to Day 28 postvaccination) will be asked to record rash 
events on the eVRC. Additionally, participants should be instructed to contact [CONTACT_370802] w ithin 72 hours of onset when 
reported from Day 1 to Day 28 postvaccination. If rash assessment cannot occur at a planned 
visit (Visit 2, Visit 3, or Visit 4) within 72 hours of the participantâ€™s rash onset, then the rash 
should be assessed by [CONTACT_370803]. Details of the rash assessment 
should be documented on the appropriate eCRF, as specified in the data entry guidelines.
8.4 Adverse Events , Serious Adverse Events ,and Other Reportable Safety Events
The definitions of an AE or SAE, as well as the method of recording, evaluating, and 
assessing causality of AE and SAE and the procedures for completing and transmitting AE, 
SAE, and other reportable safety event reports can be found in Appendix 3 .
Adverse events, SAEs, and othe r reportable safety events will be reported by [CONTACT_2299] 
(or, when appropriate, by a caregiver, surrogate, or the participant's legally authorized 
representative).
The investigator and any designees are responsible for detecting, documenting, and rep orting 
events that meet the definition of an AE or SAE as well as other reportable safety events. 
Investigators need to document if an SAE was associated with a medication error, misuse, or 
abuse. Investigators remain responsible for following up AEs , SAEs , and other reportable 
safety events for outcome according to Section 8.4.3.
08MVGC
08SK8Z
PRODUCT:   V181  57
PROTOCOL/AMENDMENT NO.:   [ADDRESS_463943] to seriousness, 
intensity/toxicity and causality .
8.4.[ADDRESS_463944] be reported by [CONTACT_093] .
All MAAEs, SAEs, and deaths that occur from the time of randomization through Month 12 
postvaccination (extended safety follow -up period) must be reported by [CONTACT_093], 
regardless of whether the events are considered to be vaccine related by [CONTACT_093] .
Investigators are not obligated to actively seek AE sor SAEs or other reportable safety events 
in former study participants. However, if the investigator learns of any SAE, including a 
death, at any time after a participant has been discharged from the study, and he/she 
considers the event to be reasonably related to the study intervention or study participation, 
the investigator must promptly notify the Sponsor.
All initial and follow -up AEs, SAEs, and other reportable safety events will be recorded and 
reported to the Sponsor or designee within the time frames as indicated in Table [ADDRESS_463945]:   V181  58
PROTOCOL/AMENDMENT NO.:   003 -01  
V181 -003-01FINAL PROTOCOL 14-JUL-2022
Table 2 Reporting Time Periods and Time Frames for A dverse Events and Other 
Reportable Safety Events
Type of EventReporting Time 
Period:
Consent to 
Randomization/ 
AllocationReporting Time 
Period:
Randomization/ 
Allocation 
through 
Protocol-
specified 
Follow -up 
PeriodReporting Time 
Period:
After the Protocol -
specified F ollow -up 
PeriodTime Frame to 
Report Event and 
Follow -up 
Information to 
Sponsor:
NSAE Report if:
-due to protocol -
specified intervention
-causes exclusion
-participant is 
receiving placebo run -
in or other run -in 
treatmentReport all Not required Per data entry 
guidelines
SAE Report if:
-due to protocol -
specified intervention
-causes exclusion
-participant is 
receiving placebo run -
in or other run -in 
treatmentReport all Report if:
-drug/vaccine 
related.
-any death until 
participant 
completion of study
(Follow ongoing to 
outcome)Within 24 hours of 
learning of event
Pregnancy/Lactation 
ExposureReport if:
-participant has been 
exposed to any 
protocol- specified 
intervention (eg, 
procedure, washout or 
run-in treatment 
including placebo run -
in)Repo rt all Previously reported â€“
Follow to 
completion/terminati
on; report outcomeWithin 24 hours of 
learning of event
Cancer Report if:
-due to intervention
-causes exclusionReport all Not required Within 5 calendar days 
of learning of event
(unless serious)
Overdose Report if:
-receiving placebo 
run-in or other run- in 
medication Report all Not required Within 5 calendar days 
of learning of event
NSAE=nonserious adverse event; SAE=serious adverse event
8.4.2 Method of Detecting AE s, SAE s,and Other Reportable Safety Events
Care will be taken not to introduce bias when detecting AE sand/or SAEs and other 
reportable safety events. Open- ended and nonleading verbal questioning of the participant is 
the preferred method to inquire about AE occurrence.
08MVGC
08SK8Z
PRODUCT:   V181  59
PROTOCOL/AMENDMENT NO.:   003 -01  
V181 -003-01FINAL PROTOCOL 14-JUL-2022
8.4.3 Follow -up of AE, SAE ,and Other Reportable Safety Event Information
After the initial AE/SAE report , the investigator is required to proactively follow each 
participant at subsequent visits/contacts. All AE s, SAE s, and other reportable safety events,
including pregnancy and exposure during breastfeeding, ECI s, cancer, and overdose will be 
followed until resolution, stabilization, until the event is otherwise explained, or the 
participant is lost to follow -up (as defined in Section 7.3 ). In addition, the investigator will 
make every attempt to follow all nonserious AEs that occur in randomized participant s for 
outcome. Further information on follow -up procedures is given in Appendix 3.
8.4.4 Regulatory Reporting Requirements for SAE
Prompt notification (within 24 hours) by [CONTACT_88701] a study intervention under clinical investigation are met.
The Sponsor has a legal responsibility to notify both the local regulatory authority and other 
regulatory agencies about the sa fety of a study intervention under clinical investigation. The 
Sponsor will comply w ith country -specific regulatory requirements and global laws and 
regulations relating to safety reporting to regulatory authorities , IRB/IECs, and investigators.
Investigat or safety reports must be prepared for S[LOCATION_003]R saccording to local regulatory 
requirements and Sponsor policy and forwarded to investigators as necessary.
An investigator who receives an investigator safety report describing an SAE or other 
specific safety i nformation (eg, summary or listing of SAE) from the Sponsor will file it 
along with the I Band will notify the IRB/IEC, if appropriate according to local requirements .
8.4.5 Pregnancy and Exposure During Breastfeeding
Although pregnancy and infant exposure durin g breastfeeding are not considered AEs, any 
pregnancy or infant exposure during breastfeeding (spontaneously reported to the 
investigator or their designee) that occurs in a participant during the study are reportable to 
the Sponsor.
All reported pregnanci es must be followed to the completion/termination of the pregnancy.
Any pregnancy complication will be reported as an AE or SAE.
The medical reason (example: maternal health or fetal disease) for an elective termination of 
a pregnancy will be reported as a n AE or SAE. Prenatal testing showing fetus will be born 
with severe abnormalities/congenital anomalies that leads to an elective termination of a 
pregnancy will be reported as an SAE for the fetus.
Pregnancy outcomes of ectopic pregnancy, spontaneous abortion, missed abortion, benign 
hydatidiform mole, blighted ovum, fetal death, intrauterine death, miscarriage, and stillbirth 
08MVGC
08SK8Z
PRODUCT:   V181  60
PROTOCOL/AMENDMENT NO.:   [ADDRESS_463946] be reported as serious events (Important Medical Events). If the pregnancy continues to 
term, the outcome (he alth of infant) must also be reported.
8.4.6 Disease -related Events and/or Disease -related Outcomes Not Qualifying as 
AEs or SAEs
Not applicable for this study.
8.4.[ADDRESS_463947]
Each participant will be provided an eVRC to report solicited and unsolicited AEs (Section 
8.1.10).
[IP_ADDRESS] Solicited Adverse Events
Solicited AEs for this study are summarized in Table 3.
Table 3 Solicited Adverse Events for V181 -003
Type of Solicited 
Adverse EventPredefined Solicited Adverse 
Events Solicited Time Period
Injection site ï‚·Injection -site pain/tenderness
ï‚·Injection- site erythema/redness
ï‚·Injection- site swellingDay 1 through Day 5 
postvaccination
Systemic ï‚·Fatigue (tiredness)
ï‚·Headache
ï‚·Myalgia (muscle pain)
ï‚·Rash
ï‚·Arthralgia (joint pain)Day 1 through Day 28
postvaccination
All solicited injection -site AEs will be considered related to study intervention. The 
investigator will assess all solicited injection -site AEs for overall intensity grade , and all 
solicited systemic AEs for both overall intensity grade and causality (Appendix 3).
08MVGC
08SK8Z
PRODUCT:   V181  61
PROTOCOL/AMENDMENT NO.:   003 -01  
V181 -003-01FINAL PROTOCOL 14-JUL-2022
In addition, the investigator will review all solicited AEs for the following:
ï‚·Is the event a symptom of another diagnosis?
ï‚·Is the event ongoing at the end of the solicited period?
ï‚·Does the event meet serious criteria?
Investigators are responsible for reviewing, assessing and reporting data entered in the eVRC
on the appropriate eCRF(s) as specified in the data entry guidelines. In addition, s olicited 
injection- site AEs and solicited systemic AEs reported by [CONTACT_370804] â€™s database.
[IP_ADDRESS] Unsolicited Adverse Events
Unsolicited AEs for this study are events that are either not predefined in Table 3or 
predefined in Table [ADDRESS_463948] to seriousness, overall intensity grade , and causality.
8.5 Treatment of Overdose
In this study, an overdose is any dose higher than one dose of the investigational V181 
vaccine/placebo.
No specific information is available on the treatment of overdose.
8.6 Pharmacokinetics
PK parameters will not be evaluated in this study.
8.7 Pharmacodynamics
Pharmacodynamic parameters will not be evaluated in this study.
08MVGC
08SK8Z
	
 <

	

 	
		

 		
BB ))&5'*.(/&(4*,	'('-
0):+)!*!:):+/!*$ )!0+ *)0+0$) $+%! !*&++*)
0&&?!1:*! ?!&&%%)!:+)00$)$+%! !* &++*B
Z#
0+0$)$+++*
Z0)/+ !)$-+$  :&0+ 1$)!%-)!)+2 -7
Z0)/+ !)$-+$ 0+  :&
BD 4('-'*(/.(/')&(E'--.4('- '*(/
8&).* !*(!*&$+*)!&!")!8&).*  !*+)/&$)
!)!)$-=
B:= A/6)&*-/!!)+C$!+ )+$)&!!,*)!==,:*!0!*:+*$ +	+&))!&+:+/!
!,*)!=
B:=: (&--,*+!1:+*$+?!&&%*$*))!!)2#-7$)& !!,*)!==
,*+!1:+*$+ -%+:)0)+*$&))!?!)) ,:+=
B:=< 
&*-&'.
A((-'-A/C$!+ )$+!1))+) ):+!+$)&!!,*)! ==
B:=8 /('--).&(,-/	'--)-'+'-'&.-4 ).0
+)!*!:)?+*!/!1&	!)+/)!*)!* )!$)$-!)+/)!=
D 


	!*)!$)&!)))!)!*&&-!)+)1-:+ *$+0+))$-=00)+)
)$-%1$%$):+!+)-$%&!!1*1+  ):+! +-K+9-
*+--:)+)))!)!*& )+&))) -:)))
:+)*&?!&&% 2*!))?!)8J$!&!.	D7= 1)>:&+)+-+
)+	*0!+ )+-&- 0)+):+)*&% 0!&!"%$):+!+)
$%&!!1?!&&%*$ )!,
+0+*!) ,0+))$-=)*
>:&+)+-&-?!&&%*&+&-!)!0!!),=
09*&CCI CCI
6.=
PRODUCT:   V181  63
PROTOCOL/AMENDMENT NO.:   003 -01  
V181 -003-01FINAL PROTOCOL 14-JUL-2022
9.1 Statistical Analysis Plan Summary
Key elements of the statistical analysis plan are summarized below; the comprehensive plan 
is provided in Section 9.2 through Section 9.12.
Study Design Overview A Phase 2, Randomized, Double -Blind, Multicenter 
Study to Evaluate the Safety and Immunogenicity 
of Three Different Potency Levels of V181 
(Dengue Quadrivalent Vaccine rDENVÎ”30 [live, 
attenuated]) in Healthy Adults
Treatment Assignment There are 4 vaccination arms. Participants will be 
assigned randomly in a 2:4:4:1ratio to the V181 
High Potency L evel Group , V181 M idPotency 
Level Group , V181 Low Potency Level Group , or 
Placebo using an IRT. A double -blind/masking 
technique will be used .
Analysis Populations Immunogenicity: Per -Protocol Population
Safety: All Participants as Treated (Ap aT)
Primary Endpoint(s) Immunogenicity (Primary):  Dengue virus -
neutralizing antibody GMTs for each of the 4 
dengue serotypes at Day 28 postvaccination as 
measured by 
[CONTACT_370805] (Primary): Vaccine -related serious adverse 
events (SAEs) from Day 1 through Day 28 
postvaccination
Key Secondary Endpoint s Safety (Secondary):
ï‚·Solicited injection -site adverse events (AEs) of 
pain, erythema, and swelling from Day 1 through 
Day 5 postvaccination
ï‚·Solicited systemic AEs of rash , headache, fatigue 
(tiredness), myalgia (muscle pain) , and arthralgia 
(joint pain) from Day 1 through Day 28 
postvaccination
Statistical Methods for Key Immunogenicity
AnalysesTo address the primary immunogenicity non-
inferiority objective, the comparison between groups 
will be made based on serotype- specific GMTs for the 
4 dengue serotypes at Day 28 postvaccination. The 
estimation of the GMT ratios and the corresponding 
95% CIs will be calculated using a linear model with
the log -transformed antibody titer as the response and 
a single term for vaccination group.
08MVGC
08SK8Z
PRODUCT:   V181  64
PROTOCOL/AMENDMENT NO.:   [ADDRESS_463949] to the 
analyses that will be perfor med. Adverse events 
(specific terms as well as SOC terms) are either 
prespecified as â€œTier1â€ endpoints or will be 
classified as belonging to â€œTier 2â€ or â€œTier 3â€ based 
on the number of events observed. There are no 
Tier 1 events for this protocol. Tier 2 p arameters 
will be assessed via point estimates with 95% CIs 
provided for differences in the proportion of 
participants with events (Miettinen and Nurminen 
[M&N] method [1985] [Miettinen, O. and 
Nurminen, M. 1985] ). Safety endpoints that are not 
Tier 1 or 2 events are considered Tier 3 events. 
Only point estimates by [CONTACT_176005] 3 safety parameters.
Interim Analyses There are no planned interim analyses for this study.
Multiplicity No multiplicity adjustment is needed for this study as 
success is required on all 4 dengue serotypes .
Sample Size and Power The overall sample size will be approximately 1265
with 230participants in the high potency group , 460 
participants in each of the mid and low potency 
group s,and 115 participants in the placebo group . 
The study has an overall power of > 95% to establish 
that the V181 Low Potency Level is non -inferior to 
the V181 Mid Potency Level for all four serotype s at 
an overall one -sided, 2.5% alpha -level.
9.2 Responsibility for Analyses/In -house Blinding
The statistical analysis of the data obtained from this study will be the responsibility of the 
Clinical Biostatistics department of the Sponsor . This study will be conducted as a 
double -blind study under in -house blinding procedures.
The Clinical Biostati stics department will generate the randomized allocation schedule(s) for 
study treatment assignment. Randomization will be implemented in an IRT . The primary 
safety and immunogenicity evaluation period for this study is defined as the period from Day 
1 through Day 28 postvaccination. A CSR will be produced to present the results for this 
time period in order to inform potency specifications for the V181 vaccine. The official, final 
database for the Day 28 analysis will not be unblinded until medical/scientific review has 
been performed, protocol deviations have been identified, and data have been declared final 
and complete. After the Day 28 postvaccination visit, participants will be followed for safety 
(SAEs and deaths only) and immunogenicity through Month [ADDRESS_463950] of the trial will be unblinded to vaccination group assignments. A blinded 
08MVGC
08SK8Z
	
 <A

	

 	
		

 		
 !*& !)+!1) ?!&& !)+))$-0)+#-)+ $1()
:)/**!)!=/)!1)+)$-!):+&:+)!*!: ),:+0!&:+&
+&1)2721&!!*&+*
*!)7?!&&+ !%&! ))+) )1+$:
!1 )$)!&)0!&)$-&-+* :&)0&&? !1)()20!&7
)%&*9=
D8 0,'4//
/*'-%L*)!/-:)0))$-+))!,*)!= =
D9 -0//-.,'-/  $1!*!)-0)-:!)))?!&&%/&$)+ &!)%&?=
D9: **)-'-(0-. -.,'-/+! +-  $1!*!)-.:!)
#1$/!+$	$)+&!"!1)!%-J(0+*0)1$ +)-:)#-
:)/**!)! $+%-=
D9< 10-.,'-/

!!)!&*+!:)!00)- $+!:+/!!,*)! ====/+&&0)-
)&+%!&!)-:+0!&0+*/**!?!&&%%-*& !!*&+/!?0&&0)-)
*&&*)=,&!*!)$&!*!)!L*)!	!)-) ! *
.?!&&%$  +!"
/+&&%- >! $ +:+)!)!)-=:+! +-0)- /&$)!:+!0+)!
)$-?!&&%#-)+$1#-:)/**!)!=
09*&CCICCI
6.=
PRODUCT:   V181  66
PROTOCOL/AMENDMENT NO.:   003 -01  
V181 -003-01FINAL PROTOCOL 14-JUL-2022
Primary Safety Endpoints
ï‚·Vaccine -related SAEs from Day 1 through Day 28 postvaccination
Secondary Safety Endpoints
ï‚·Solicited injection -site AEs of injection- site pain, injection- site erythema, and injection-
site swelling from Day 1 through Day 5 postvaccination
ï‚·Solicited systemic AEs of rash , headache, fatigue (tiredness), myalgia (muscle pain) , and 
arthralgia (joint paint )from Day 1 through Day 28 postvaccination
Additional Safety Endpoints
ï‚·Unsolicited AEs from Day 1 through Day 28 postvaccination
ï‚·Elevated temperature ( â‰¥100.4Â°F [38.0Â°C] oral equivalent) from Day 1 through Day 28 
postvaccination
ï‚·All MAAEs, SAEs , and deaths through completion of study participation
9.[ADDRESS_463951] the results of the p rimary 
immunogenicity endpoints. Potential deviations that may result in the exclusion of a 
participant from the PP population for all immunogenicity analyses include:
ï‚·Prevaccination baseline blood sample test result is seropositive for any of the 4 dengue
serotypes by [CONTACT_370806]. Seropositivity will be defined as having VRNT at or above the 
LLOQ of the assay.
ï‚·Failure to receive correct clinical material as per randomization schedule
ï‚·Receipt of prohibited medication or prohibited vaccine before study vaccination or 
though Day 28 postvaccination.
ï‚·Collection of blood sample at the timepoint for the analysis outside of the pre -specified 
window ,as described in Section 1.3
The final determination on protocol deviations ,and thereby [CONTACT_370807] ,will be made before the unblinding of the database and will be documented in a 
separate memo. The key immunogenicity analyses will also be performed using the Full 
Analysis Set (FAS) population, which consists of all randomized participants who receive 
08MVGC
08SK8Z
	
 <@

	

 	
		

 		
)$-/**!)!/)&)/&!+&1-+$&)= +)!*!:)?!&&%!*&$!)
/**!)!1+$:)))-++ !"0+)&-!0!  $1!*!)-)$!1)


,::$&)!=L$) )?!&&% 0+ !!1)=
D>< 10-0//',)'-/

&&+)!*!:)+)2
:7::$&)!?!&&%$0 +)&-!00)-)
!)!)$-=
:::$&)!*!)0&&+ !": +)!*!:)?+*!/)
&)0)$-/**!K:&*%=+)!*!:)?!&&%!*& $!)/**!)!1+$:
*++:!1)))$-/**!K:&*%)-*)$&&-+*!/ 0+)&-!00)-
)$!1)
:::$&)!=
+ ):+)!*!:))!?!&& %)/**!)!1+$:)
?!*)-++ !"=
D; /(4'./!*)!*+!%)))!)!*& )))+) :+! +-*+-
%L*)!/=,))!)!*& )+&))>:&+)+-%L*)!/ ?!&&%0$+)+*+!%!
),
=9-!  $1!*!)-&-)%:+0+ +$   +!"!%&
2,*)!D=<=7=0)-&-+$  +!"!,*)! D=<==&)+?!
))&&))!)!*&))?!&&%*$*)))cQ=A2 	!7&/&=
D;: /(4'./1'&**)-'-(0-0//
:+! +--:)!0	!0+!+!)-0J(0+*1$ +)-:2#.
#.#.#.7?!&&%+%-	!)) 0	!0+!+!)-2
*++:!1)*1$+)-:7*$*))cQ=A&/ &2	!7=
+*
1$+)-:)-:))%))+B
8BJ(
>KJ(-d=<@
+$8BJ(
>KJ(-_=<@
?+J( >+:+))J()-:)/**!)!!)?) *-/&
1+$:J( -+:+))J()#-:)/**!)!!)(!) *-
/&1+$:=.)! )!0)J(+)!* :$))!0) *++:!1DAN
?!&&%*&*$&)$!1)	!)+!%$)!?!))/+!*)! )0+ &!+ &$)!&!"!1
)&1	)+0+ )!%-)!)+)+:!1& )+ 0+/**!)!1+$:=
:!))! )?!&&%*&*$&)%->:)!)!1) )! )0) 0)
)$+&&1/&$)?!&&%+!/%->:)!)! 1)0) 0)
)$+&&1/&$%) &=))!)!*&*+!)+! 0+	!0+!+!)-+C$!+
)))&?+%$0)?	!DAN*0!*!)+/&0J( +)!2?
)*-/&/=(!)*-/&7%!11+)+)=< @=
09*&CCI
6.=
	
 <

	

 	
		

 		




5&::+==D6=
%& 
&-!,)+)1-0+  $1!*!)-+!%&
-.,'-
A&+
$/(&,'-!
*'-%&*&02/
),,'&2
,,&'(4/(4'.+-0//
',)'-//-
,,&'(4
&*&0-.,'-
#1$/!+$	$)+&!"!1
)!%-J(0+*0
)1$+)-:)
#-:)/**!)!
 $+%-
,)	!)+!%$)!?!)
)/+!*
)! )0+ 
&!+ &%
2)! )DAN
	/&$7


,(!!1)
?!&&)%
! :$)
Q*0!*!)+/&R

,Q
$&&
&-!,)RJ(QJ ) +!*(!)+RQ+	+)*&
Q+! +-::+*R,Q,$::+)!/::+*=
%.)! )!0)1$/!+$	$)+&!"!1)!%-J(*  :$))!0)*++:!1DAN
?!&&%*&*$&)$!1)	!)+!%$)!?!))/+!* )! )0+ &!+ &$)!&!"!1)&1	
)+0+ )!%-)!)+)+:!1&)+ 0 +/**!)!1+$:=
D;< /(4'./1'&10-0//
,0)-)&+%!&!)-?!&&%%-*&!!*&+/!?0 &&+&/):+ )+=
&-!00)-?!&&%:+0+ 0+*0) )*-/&1+$:2
8!1)*-/&(!)*-/&?)*- /&7/+$:&*%
0&&?!1)!+::+*2 %&A7=)!+!00+?!)+:*)))&-))?!&&%
:+0+ =
/+/)2:*!0!*)+ ?&&,)+ 7 +!)+:+	:*!0!
U!+V:!)+?!&&%*&!0!%&1!1)U!+ V+U!+V%)
$ %+0/)%+/=
:+)0)-&-!?!&&%: +0+ ?!)* :+!
%)?)8!1)*-/&/)(!)*-/ &?&&)
?)*-/&/)(!)*-/&=!&-! ?!&&!*&$* :+!
?!))0&&?!1)%&B/+&&
.$  +-&!*!)!L* )!!)
.&!*!)
-) !*
.!)+!%$)!0 >! $ ) :+)$+=

&:2-/
,0)-:+ )++/+/)0:*!&!)+)))+ !)!0! *)!)$)
U!+V0)-:!)))?!&&%$%L*))!0+)!&) )!10+))!)!*&!1!0!**=
++!+/)0+)!:+)*&)+!0+ &0)--:)!=
09*&CCI
6.=
PRODUCT:   V181  69
PROTOCOL/AMENDMENT NO.:   003 -01  
V181 -003-01FINAL PROTOCOL 14-JUL-2022
Tier 2 Events
Tier 2 parameters will be assessed via point estimates with 95% CIs provided for differences 
in the proportion of participants with events (Miettinen and Nurminen [M&N] method [1985]
[Miettinen, O. and Nurminen, M. 1985] ).
Membership in Tier [ADDRESS_463952] 4 events was chosen because the 95% confidence interval for 
the between -group difference in percent incidence will always include zero when treatment 
groups of equal size each have less than 4 events and thus would add little to the 
interpretation of potentially meaningful differences. Because many 95% CIs for Tier [ADDRESS_463953] AE categories consisting of the proportion of participants with any AE, a vac cine-
related AE, an MAAE, a vaccine -related MAAE, an SAE, a vaccine -related SAE, 
discontinuation due to an AE, and death will be considered Tier 2 endpoints. Solicited 
injection- site AEs (pain, erythema, and swelling) from Day 1 through Day 5 postvaccinati on, 
solicited systemic AEs ( rash, headache, fatigue [tiredness], myalgia [muscle pain], and
arthralgia [joint pain] ) from Day [ADDRESS_463954]:   V181  70
PROTOCOL/AMENDMENT NO.:   003 -01  
V181 -003-01FINAL PROTOCOL 14-JUL-2022
Table 5 Analysis Strategy for Safety Para meters
9.6.3 Summaries of Baseline Characteristics, Demographics, and Other Analyses
The comparability of the vaccination groups for each relevant characteristic will be assessed 
by [CONTACT_113827]/or graphs. No statistical hypothesis tests will be performed on these 
characteristics. The number and percentage of participants screened and randomized, the 
primary reasons for screening failure, and the primary reason for discontinuation will be 
displayed. Demographic variables (e g, age), baseline characteristics, primary and secondary Safety 
Tier Safety Endpointa95% CI for 
Treatment 
ComparisonDescriptive 
Statistics
Tier 2 Any AEaX X
Any vaccine -related AEaX X
Any MAAEaX X
Any vaccine -related MAAEaX X
Any SAEaX X
Any vaccine -related SAEa X X
Discontinuation due to AEaX X
DeathaX X
Solicited injection- site AEs:  pain, erythema, 
and swellingX X
Solicited systemic AEs: rash, headache, fatigue 
(tiredness), myalgia (muscle pain) , and 
arthralgia (joint pain)X X
Elevated temperature ( â‰¥100.4Â°F [38.0Â°C] oral 
equivalent) X X
Specific AEs by [CONTACT_370808](incidence â‰¥4 
participants in one of the vaccination groups)X X
Tier 3 Specific AEs by [CONTACT_370809](incidence <4 
participants in all of the vaccination groups)X
AE = adverse event; CI = confidence interval; MAAE â€“medically attended adverse event; PT = preferred 
term; SAE = serious adverse event; SOC=system organ class; X = results will be provided
  aThese endpoints are broad AE categories. For example, descriptive statistics for the safety endpoint of 
â€œAny AEâ€ will provide the number and percent age of participants with at least one AE. 
  bIncludes only those endpoints not already pre- specified as Tier [ADDRESS_463955]:   V181  71
PROTOCOL/AMENDMENT NO.:   003 -01  
V181 -003-01FINAL PROTOCOL 14-JUL-2022
diagnoses, and prior and concomitant therapi[INVESTIGATOR_370783].
9.7 Interim Analyses
No interim analyses are planned for this study. Participant safety will be monitored by [CONTACT_370810] (Appendix 1).
An unblinded statistician and statistical programmer not directly involved in the conduct of 
the study will be responsible for providing unblinded report deliverables to the eDMC.
Details will be provided in the eDMC charte r.
9.8 Multiplicity
No multiplicity adjustment is needed for this study as success is required on all 4 dengue 
serotypes .
9.9 Sample Size and Power Calculations
9.9.1 Sample Size and Power for Immunogenicity Analyses
This study will randomize participants in a 2:4:4:1 ratio into the 4 vaccination groups ( V181 
High Potency Level Group, V181 Mid Potency Level Group, V181 Low Potency Level 
Group , and Placebo). The overall sample size will be approximately 1265 with 
230participants in theHigh Potency Level G roup, 460 pa rticipants in each of the M id and 
Low P otency Level G roups, and 115 participants in the placebo group .The study has an 
overall power of >95% to establish that the V181 Low Potency Level is non -inferior to the 
V181 Mid P otency Level for all four serotypes at an overall one -sided, 2.5% alpha -level. The 
power and sample size are based on the following assumptions: 1) an approximately 15% 
non-evaluable rate, 2) the non -inferiority margin of 0. 67, 3) the true GMT ratio is assumed to 
be 1, and 4) the standard deviation of the natural -log titers is estimated to be 1.[ADDRESS_463956] 1 vaccine -related SAE in this study depends on the 
number of participant s vaccinated and the underlying percentage of participants with a 
vaccine -related SAE in the study population. If the underlying incidence of a vaccine -related 
SAE is 0.30% (1 of every 333 participant s receiving the vaccine), there is a 50% chance of 
observing at least 1 vaccine -related SAE among 230 participant s in theV181 High Potency 
Level vaccination group. If the incidence rate is 1 of every 1 44recipi[INVESTIGATOR_840] (0.69%), there is an 
80% chance of obser ving at least 1 vaccine -related SAE . If no vaccine -related SAEs are 
observed among the 230participant s in theV181 High P otency Level vaccination group, this 
study will provide 97.5% confidence that the underlying percentage of participants with 
vaccine -related SAE is <1.6% in the V181 High P otency Level vaccination group.
08MVGC
08SK8Z
PRODUCT:   V181  72
PROTOCOL/AMENDMENT NO.:   003 -01  
V181 -003-01FINAL PROTOCOL 14-JUL-2022
Table 6 summarizes the percentage point differences between the 2 vaccination groups that
could be detected with 80% probability for a variety of hypothetical underlying incidences of
an AE. These calculations assume 230participants in the V 181High Potency Level group 
and 115 participants in the Placebo group , and are based on a 2- sided 5% al pha level. The 
calculations are based on an asymptotic method proposed by [CONTACT_370811][Farrington, C. P. and Manning, G. 1990]; no multiplicity adjustments were made.
Table 6 Differences in Incidence of Adverse Event Rates Between the 2 Vaccination 
Groups That Can be Detected With an ~80% Probability (Assuming a 2 -Sided 5% Alpha 
Level With 230Participants in theV181 High Potency Level Group and 115 Participants in 
the Placebo Group)
Incidence of an Adverse Event Risk Difference
V181 High Potency Level Group 
(%) Placebo (%) Percentage Points
5.7 0.1 5.6
9.8 2.0 7.8
14.7 5.0 9.7
21.9 10.0 11.9
28.3 15.0 13.3
34.3 20.0 14.3
45.5 30.0 15.5
Incidences presented here are hypothetical and do not represent actual adverse experiences in either 
group. Based on an asymptotic method proposed by [CONTACT_63541] (1990) [Farrington, 
C. P. 1990]
If the underlying incidence of a vaccine -related SAE is 0.15% (1 of every 665participant s 
receiving the vaccine), there is a 50% chance of observing at least 1 vaccine -related SAE
among 460 participant s in theV181 Mid Potency Level and V181 Low Potency Level 
Groups.If the incidence rate is 1 of every 287recipi[INVESTIGATOR_840] ( 0.35%), there is an 80% chance of 
observing at least 1 vaccine -related SAE . If no vaccine -related SAEs are observed among the
460 participant s in each of the V181 Mid Potency Level and V181 Low Potency Le vel 
Groups, this study will provide 97.5% confidence that the underlying percentage of 
participant s with vaccine -related SAE is <0.9% in each of the V181 Mid Potency Level and 
V181 Low Potency Level Groups.
Table 7 summarizes the percentage point differences between the 2 vaccination groups that
could be detected with 80% probability for a variety of hypothetical underlying incidences of
an AE. These calculations assume 460participants in the V 181Mid Potency Level or V181 
Low Potency Level G roup and 115 participants in the P lacebo group , and are based on a 2 -
sided 5% alpha level. The calculations are based on an asymptotic method proposed by 
[CONTACT_63541] (1990) [Farrington, C. P. and Manning, G. 1990]; no multiplicity 
adjustments were made.
08MVGC
08SK8Z
PRODUCT:   V181  73
PROTOCOL/AMENDMENT NO.:   003 -01  
V181 -003-01FINAL PROTOCOL 14-JUL-2022
Table 7 Differences in Incidence of Adverse Event Rates Between the 2 Vaccination 
Groups That Can be Detected With an ~80% Probability (Assuming a 2 -Sided 5% Alpha 
Level With 460Participants in theV181 Mid Potency Level or V181 Low Potency Level 
Group and 115 Participants in the Placebo Group)
Incidence of an Adverse Event Risk Difference
V181 Mid/ Low Potency Level 
Group (%) Placebo (%) Percentage Points
5.0 0.1 4.9
9.0 2.0 7.0
13.8 5.0 8.8
20.8 10.0 10.8
27.1 15.0 12.1
33.0 20.0 13.0
44.2 30.0 14.2
Incidences presented here are hypothetical and do not represent actual adverse experiences in either 
group. Based on an asymptotic method proposed by [CONTACT_63541] (1990) [Farrington, 
C. P. 1990]
9.10 Subgroup Analyses
The subgroup analyses will be comprised of descriptive summary statistics for 
immunogenicity by [CONTACT_25890]. Further details of subgroup analyses will be documented 
in the sSAP .
9.11 Compliance (Medication Adherence)
Given that participan ts will receive only a single dose of 1 of 3 V181 potency levels or 
placebo, compliance will not be calculated. The number and proportion of randomized 
participants receiving each study vaccin ation will be summarized (see Section 9.12) .
9.[ADDRESS_463957]:   V181  74
PROTOCOL/AMENDMENT NO.:   003 -01  
V181 -003-01FINAL PROTOCOL 14-JUL-2022
10 SUPPORTING DOCUMENTATION AND OPERATIONAL 
CONSIDERATIONS
10.1 Appe ndix 1: Regulatory, Ethical, and Study Oversight Considerations
10.1.[ADDRESS_463958] for Clinical Trials
[COMPANY_006] Sharp & Dohme LLC, Rahway, NJ, [LOCATION_003] (MSD)
Code of Conduct for Interventional Clinical Trials
I. Introduction
A. Purpose
MSD, through its subsidiaries, conducts clinical trials worldwide to evaluate the safety and effectiveness of our 
products. As such, we are committed to designing, implementing, conducting, analyzing, and reporting these trials 
in compliance with the highest ethical and sc ientific standards. Protection of participants in clinical trials is the 
overriding concern in the design and conduct of clinical trials. In all cases, MSD clinical trials will be conducted 
in compliance with local and/or national regulations (including all applicable data protection laws and
regulations), and International Council for Harmonisation Good Clinical Practice (ICH- GCP), and also in 
accordance with the ethical principles that have their origin in the Declaration of Helsinki.
B. Scope
Highest eth ical and scientific standards shall be endorsed for all clinical interventional investigations sponsored by 
[CONTACT_19481] (parties) employed for their execution (e.g., contract research organizations, 
collaborative research efforts). This Code is not intended to apply to trials that are observational in nature, or 
which are retrospective. Further, this Code does not apply to investigator- initiated trials, which are not under the 
full control of MSD.
II. Scientific Issues
A. Trial Conduct
1. Trial Design
Except for pi[INVESTIGATOR_19354], clinical trial protocols will be hypothesis -driven to assess safety, efficacy 
and/or pharmacokinetic or pharmacodynamic indices of MSD or comparator products. Alternatively, MSD 
may conduct outcomes resea rch trials, trials to assess or validate various endpoint measures, or trials to 
determine patient preferences, etc.
The design (i.e., participant population, duration, statistical power) must be adequate to address the specific 
purpose of the trial and sh all respect the data protection rights of all participants, trial site staff and, where 
applicable, third parties . Participants must meet protocol entry criteria to be enrolled in the trial. 
2. Site Selection
MSD selects investigative sites based on medic al expertise, access to appropriate participants, adequacy of 
facilities and staff, previous performance in clinical trials, as well as budgetary considerations. Before trial 
initiation, sites are evaluated by [CONTACT_26397] (or individuals acting on behalf of MSD) to assess the ability 
to successfully conduct the trial.
08MVGC
08SK8Z
PRODUCT:   V181  75
PROTOCOL/AMENDMENT NO.:   003 -01  
V181 -003-01FINAL PROTOCOL 14-JUL-2022
3. Site Monitoring/Scientific Integrity
Investigative trial sites are monitored to assess compliance with the trial protocol and Good Clinical Practice 
(GCP). MSD reviews clinical data for accuracy, completeness, and consistency. Data are verified versus 
source documentation according to standard operating procedures. Per MSD policies and procedures, if
potential fraud, scientific/research misconduct, privacy incidents/breaches orClinic al Trial -related 
Significant Quality Issues are reported, such matters are investigated . When necessary, appropriate corrective 
and/or preventative actions are defined and regulatory authorities and /orethics review committees are 
notified.
B. Publication and Authorship
Regardless of trial outcome, MSD commits to publish the primary and secondary results of its registered trials of 
marketed products in which treatment is assigned, according to the pre -specified plans for data analysis. To the 
extent scientifically appropriate, MSD seeks to publish the results of other analyses it conducts that are important 
to patients, physicians, and payers. Some early phase or pi[INVESTIGATOR_26346] -generating rather 
than hypothesis testing; in such ca ses, publication of results may not be appropriate since the trial may be 
underpowered and the analyses complicated by [CONTACT_19482].
MSDâ€™s policy on authorship is consistent with the recommendations published by [CONTACT_26399] (ICMJE). In summary, authorship should reflect significant contribution to the design and 
conduct of the trial, performance or interpretation of the analysis, and/or writing of the manuscript. All named 
authors must be able to defend the trial results and conclusions. MSD funding of a trial will be acknowledged in 
publications.
III. Participant Protection
A. Regulatory Authority and Ethics Committee Review (Institutional Review Board [IRB]/Independent Ethics 
Committee [IEC])
All protocols and protocol amendments will be submitted by [CONTACT_88708]/authorization before implementation of the trial or amendment, in compliance with local and/or 
national regulations.
The protocol, protocol amendment(s), informed consent form, investigatorâ€™s brochure, and other relevant trial 
documents must be reviewed and approved by [CONTACT_2717]/IEC before being implemented at each site, in compliance 
with local and/or national regulations. Changes to the protocol that are required urgently to eliminate an 
immediate hazard and to protect participant safety may be enacted in anticipation of ethics committee approval. 
MSD will inform regulatory authorities of such new measures to protect participant safety, in compliance with 
local and/or national regulations.
B. Safety
The guiding principle in decision -making in clinical trials is that participant welfare is of primary importance. 
Potential participants will be informed of the risks and benefits of, as well as alternatives to, trial participation. At 
a minimum, trial designs will take into account the local standard of care.
All participation in MSD clinical trials is voluntary. Participants enter the trial only after informed consent is 
obtained. Participants m ay withdraw from an MSD trial at any time, without any influence on their access to, or 
receipt of, medical care that may otherwise be available to them.
C. Confidentiality
MSD is committed to safeguarding participant confidentiality, to the greatest exten t possible , as well as all 
applicable data protection rights . Unless required by [CONTACT_2371], only the investigator, Sponsor (or individuals acting on 
behalf of MSD), ethics committee, and/or regulatory authorities will have access to confidential medical records 
that might identify the participant by [CONTACT_2300].
08MVGC
08SK8Z
PRODUCT:   V181  76
PROTOCOL/AMENDMENT NO.:   003 -01  
V181 -003-01FINAL PROTOCOL 14-JUL-2022
D. Genomic Research
Genomic research will only be conducted in accordance with a protocol and informed consent authorized by [CONTACT_88709].
IV. Financial Considerations
A. Payments to Investigators
Clinica l trials are time -and labor -intensive. It is MSDâ€™s policy to compensate investigators (or the sponsoring 
institution) in a fair manner for the work performed in support of MSD trials. MSD does not pay incentives to 
enroll participants in its trials. Howev er, when enrollment is particularly challenging, additional payments may be 
made to compensate for the time spent in extra recruiting efforts.
MSD does not pay for participant referrals. However, MSD may compensate referring physicians for time spent 
on ch art review and medical evaluation to identify potentially eligible participants.
B. Clinical Research Funding
Informed consent forms will disclose that the trial is sponsored by [CONTACT_19487], and that the investigator or sponsoring 
institution is being paid or prov ided a grant for performing the trial. However, the local ethics committee may 
wish to alter the wording of the disclosure statement to be consistent with financial practices at that institution. As 
noted above, all publications resulting from MSD trials w ill indicate MSD as a source of funding.
C. Funding for Travel and Other Requests
Funding of travel by [CONTACT_19488] (e.g., to scientific meetings, investigator meetings, etc.) will be 
consistent with local guidelines and practices.
V. Investigator Commitment
Investigators will be expected to review MSDâ€™s Code of Conduct as an appendix to the trial protocol, and in signing the 
protocol, agree to support these ethical and scientific standards.
10.1.2 Financial Disclosure
Financial d isclosure requirements are outlined in the US Food and Drug Administration 
Regulations, Financial Disclosure by [CONTACT_6230] (21 CFR Part 54). It is the 
Sponsor's responsibility to determine, based on these regulations, whether a request for 
Financial d isclosure information is required. It is the investigator's/subinvestigator's 
responsibility to comply with any such request.
The investigator/subinvestigator(s) agree, if requested by [CONTACT_19489] 21 
CFR Part 54, to provide his/her financial interests in and/or arrangements with the Sponsor to 
allow for the submission of complete and accurate certification and disclosure statements. 
The investigator/subinvestigator(s) further agree to provide this information on a 
Certification/Dis closure Form, commonly known as a financial disclosure form, provided by 
[CONTACT_1034]. The investigator/subinvestigator(s) also consent to the transmission of this 
information to the Sponsor in the [LOCATION_002] for these purposes. This may involve the 
transmission of information to countries that do not have laws protecting personal data.
08MVGC
08SK8Z
PRODUCT:   V181  77
PROTOCOL/AMENDMENT NO.:   [ADDRESS_463959] this study in compliance with all applicable data protection 
regulations.
Participants will be assigned a unique identifier by [CONTACT_3433] e Sponsor. Any participant records or 
datasets that are transferred to the Sponsor will contain the identifier only; participant names 
or any information that would make the participant identifiable will not be transferred.
The participant must be informed that his/her personal study -related data will be used by [CONTACT_19490]. The level of disclosure must also be 
explained to the participant. 
The participant must be informed that his/her medical records may be exa mined by [CONTACT_88710] S ponsor, by 
[CONTACT_6667]/IEC members, and by [CONTACT_6668].
[IP_ADDRESS] Confidentiality of Data
By [CONTACT_12570], the investigator affirms to the Sponsor that information furnished to 
the investigator by [CONTACT_19492], and such information will 
be divulged to the IRB , IEC ,or similar or expert committee; affiliated institution and 
employees, only under an appropriate understanding of confidentiality with such board or 
committee, affiliated institution and employees. Data generated by [CONTACT_19493], except to the extent that it is included in a 
publication as provided in the Publications section of this protocol.
[IP_ADDRESS] Confidentiality of Participant Records
By [CONTACT_12570], the investigator agrees that the Sponsor (or Sponsor representative), 
IRB/IEC, or regulatory authority representatives ma y consult and/or copy study documents to 
verify worksheet/ CRF data. By [CONTACT_17317], the participant agrees to this 
process. If study documents will be photocopi[INVESTIGATOR_88648]/ CRF information, the participant will be identified by [CONTACT_19494]; full 
names/initials will be masked before transmission to the Sponsor.
By [CONTACT_12570], the investigator agrees to treat all participant data used and 
disclosed in connection with this study in accordance with al l applicable privacy laws, rules 
and regulations.
[IP_ADDRESS] Confidentiality of IRB/IEC Information
The Sponsor is required to record the name [CONTACT_19525]/IEC that reviews and 
approves this study. The Sponsor is also required to document that each IRB/IEC meets 
regulatory and ICH GCP requirements by [CONTACT_26389]/IEC members and to make these records available for 
regulatory agency review upon request by [CONTACT_19496] .
08MVGC
08SK8Z
PRODUCT:   V181  78
PROTOCOL/AMENDMENT NO.:   003 -01  
V181 -003-01FINAL PROTOCOL 14-JUL-2022
10.1.4 Committees Structure
[IP_ADDRESS] Executive Oversight Committee
The EOC is comprise d of members of Sponsor Senior Management. The EOC will receive 
and decide upon any recommendations made by [CONTACT_113836].
[IP_ADDRESS] External D ata Monitoring Committee
To supplement the routine study monitoring outlined in this protocol, an external DMC will 
monitor the interim data from this study. The voting members of the committee are external 
to the Sponsor. The members of the DMC must not be involved with the study in any other 
way (eg, they cann ot be study investigators) and must have no competing interests that could 
affect their roles with respect to the study.
The DMC will make recommendations to the EOC regarding steps to ensure both participant 
safety and the continued ethical integrity of t he study. Also, the DMC will review interim 
study results, consider the overall risk and benefit to study participants and recommend to the 
EOC whether the study should continue in accordance with the protocol.
Specific details regarding composition, responsibilities, and governance, including the roles 
and responsibilities of the various members and the Sponsor protocol team ; meeting 
facilitation; the study governance structure; and requirements for and proper documentation 
of DMC reports, minutes, and rec ommendations will be described in the DMC charter that is 
reviewed and approved by [CONTACT_63548].
10.1.[ADDRESS_463960] 
proprietary inform ation and t o provide comments.
Authorship will be determined by [CONTACT_175067] .
10.1.6 Compliance with Study Registration and Results Posting Requirements
Under the terms of the FD AAA of 2007 and the EMA clinical trial Directive 2001/20/EC, the 
Sponsor of the study is solely responsible for determining whether the study and its results 
are subject to the requirements for submission to http://www.clinicaltrials.gov, 
www.clinicaltrial sregister.eu or other local registries. MSD, as Sponsor of this study, will 
08MVGC
08SK8Z
PRODUCT:   V181  79
PROTOCOL/AMENDMENT NO.:   [ADDRESS_463961] the study in an efficient and 
diligent manner and in conformance with this protocol; generally accepted standards of G CP
(eg, International C ouncil on Harmoni sation of Technical Requirements for Registration of 
Pharmaceuticals for Human Use GCP : Consolidated Guideline and other generally accepted 
standards of GCP ); and all applicable federal, state and local laws, rules and regulations 
relating to the conduct of the clinical study.
The Code of Conduct, a collection of goals and considerations that govern the ethical and 
scientific conduct of clinical investigations sponsored by [CONTACT_19487], is provided i n this appendix 
under the Code of Conduct for Clinical Trials.
The investigator agrees not to seek reimbursement from participants, their insurance 
providers , or from government programs for procedures included as part of the study 
reimbursed to the investigator by [CONTACT_1034].
The investigator will promptly inform the Sponsor of any regulatory authority inspection 
conducted for this study.
The investigator agrees to provide the Sponsor with relevant information from inspection 
observations/findings to allow the Sponsor to assist in responding to any citations resulting 
from regulatory authority inspection and will provide the Sponsor with a copy of the 
propose d response for consultation before submission to the regulatory authority. 
Persons debarred from conducting or working on clinical studies by [CONTACT_19500]â€™s studies. The investigator 
will immediately disclose in writing to the Sponsor if any person who is involved in 
conducting the study is debarred or if any proceeding for debarment is pending or, to the best 
of the investigatorâ€™s knowledge, threatened .
10.1.8 Data Quality Assur ance
All participant data relating to the study will be recorded on printed or electronic CRF unless 
transmitted to the Sponsor or designee electronically (eg, laboratory data). The investigator 
08MVGC
08SK8Z
PRODUCT:   V181  80
PROTOCOL/AMENDMENT NO.:   [ADDRESS_463962] maintain accurate documentation (source data) t hat supports the 
information entered in the CRF.
The investigator must permit study- related monitoring, audits, IRB/IEC review, and 
regulatory agency inspections and provide direct access to source data documents.
Study documentation will be promptly and f ully disclosed to the Sponsor by [CONTACT_63551], 
copying, review, and audit at reasonable times by [CONTACT_19502]. T he investigator agrees to promptly take any reasonable steps that are 
requested by [CONTACT_88713] a result of an audit or inspection to 
cure deficiencies in the study documentation and worksheets/CRFs .
The Sponsor or designee is responsible for the data management of this study including 
quality checking of the data.
Study monitors will perform ongoing source data review and verification to confirm that data 
entered into the CRF by [CONTACT_1191], comple te, and verifiable from 
source documents; that the safety and rights of participants are being protected; and that the 
study is being conducted in accordance with the currently approved protocol and any other 
study agreements, ICH GCP, and all applicable r egulatory requirements.
Records and documents, including participants' documented informed consent, pertaining to 
the conduct of this study must be retained by [CONTACT_1732] 15 years after study 
completion unless local regulations or institutional p olicies require a longer retention period. 
No records may be destroyed during the retention period without the written approval of the 
Sponsor. No records may be transferred to another location or party without written 
notification to the Sponsor.
10.1.9 Source D ocuments
Source documents provide evidence for the existence of the participant and substantiate the 
integrity of the data collected. The investigator/institution should maintain adequate and 
accurate source documents and study records that include al lpertinent observations on each 
of the siteâ€™s participants. Source documents and data should be attributable, legible, 
contemporaneous, original, accurate, and complete. Changes to source data should be 
traceable, should not obscure the original entry, and should be explained if necessary (eg, via 
an audit trail). Source documents are filed at the investigatorâ€™s site.
08MVGC
08SK8Z
PRODUCT:   V181  81
PROTOCOL/AMENDMENT NO.:   [ADDRESS_463963] be explained. The 
investigator /institution may need to request previous medical records or transfer records, 
depending on the study. Also, current medical records must be available .
10.1.10 Study and Site Closure
The Sponsor or its designee ma y stop the study or study site participation in the study for 
medical, safety, regulatory, administrative, or other reasons consistent with applicable laws, 
regulations, and GCP.
In the event the Sponsor prematurely terminates a particular study site, the Sponsor or 
designee will promptly notify that study siteâ€™s IRB/IEC as specified by [CONTACT_88714](s).
08MVGC
08SK8Z
PRODUCT:   V181  82
PROTOCOL/AMENDMENT NO.:   003 -01  
V181 -003-01FINAL PROTOCOL 14-JUL-2022
10.2 Appendix 2: Clinical Laboratory Tests
Clinical laboratory tests are not planned for this study.
08MVGC
08SK8Z
PRODUCT:   V181  83
PROTOCOL/AMENDMENT NO.:   003 -01  
V181 -003-01FINAL PROTOCOL 14-JUL-2022
10.3 Appendix 3: Adverse Events: Definitions and Procedures for Recording, 
Evaluating, Follow -up, and Reporting
10.3.[ADDRESS_463964].
10.3.2 Definition of AE
AE definition
ï‚·    An AE is any untoward medical occurrence in a clinical study participant, temporally 
associated with the use of study intervention, whether or not considered related to the 
study intervention.
ï‚·    
NOTE: An AE can therefore be any unfavorable and unintended sign (including an 
abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally 
associated with the use of a study intervention.
ï‚·    NOTE: For purposes of AE definition, study intervention (also referred to as Sponsorâ€™s 
product) includes any pharmaceutical product, biological product, vaccine, diagnostic 
agent, medical device, combina tion product, or protocol specified procedure whether 
investigational or marketed (including placebo, active comparator product, or run -in 
intervention) , manufactured by, licensed by, provided by, or distributed by [CONTACT_88715].
Events meeting the AE definition
ï‚·    Any abnormal laboratory test results (hematology, clinical chemistry, or urinalysis) or 
other safety assessments (eg, ECG, radiological scans, vital signs measurements), 
including those that worsen from baseline, consi dered clinically significant in the medical 
and scientific judgment of the investigator.
ï‚·    Exacerbation of a chronic or intermittent pre -existing condition including either an 
increase in frequency and/or intensity of the condition.
08MVGC
08SK8Z
PRODUCT:   V181  84
PROTOCOL/AMENDMENT NO.:   003 -01  
V181 -003-01FINAL PROTOCOL 14-JUL-2022
ï‚·    New conditions detected or diagnosed after study intervention administration even 
though it may have been present before the start of the study.
ï‚·    Signs, symptoms, or the clinical sequelae of a suspected drug -drug interaction.
ï‚·    Signs, symptoms, or the c linical sequelae of a suspected overdose of either study 
intervention or a concomitant medication.
ï‚·    For all reports of overdose (whether accidental or intentional) with an associated AE, the 
AE term should reflect the clinical symptoms or abnormal test result. An overdose 
without any associated clinical symptoms or abnormal laboratory results is reported using 
the terminology â€œaccidental or intentional overdose without adverse effect.â€
Events NOT meeting the AE d efinition
ï‚·    Medical or surgical procedure (eg, endoscopy, appendectomy): the condition that leads to 
the procedure is the AE.
ï‚·    Situations in which an untoward medical occurrence did not occur (social and/or 
convenience admission to a hospi[INVESTIGATOR_307]).
ï‚·    Anticipated day -to-day fl uctuations of pre -existing disease(s) or condition(s) present or 
detected at the start of the study that do not worsen.
ï‚·    Surgery planned before informed consent to treat a pre -existing condition that has not 
worsened.
ï‚·    Refe r to Section 8.4.6 for pr otocol -specific exceptions.
Definition of Unsolicited and Solicited AE
ï‚·    An unsolicited AE is an AE that was not solicited using an eVRC and that is 
communicated by a participant who has signed the informed consent. Unsolicited AEs 
include serious and n onserious AEs .
ï‚·    Solicited AEs are predefined local (at the injection site) and systemic events for which 
the participant is specifically questioned, and which are noted by [CONTACT_370812] .
Definition of MAAE
ï‚·AEs in which medical attention is received during an unscheduled non -routine outpatient 
visit, such as an emergency room visit, office visit, or an urgent care with any medical 
personnel for any reason. Routine visits are not considered MAAEs. Examples of routine 
visits include physical examination, wellness visit, or vaccinations.
08MVGC
08SK8Z
PRODUCT:   V181  85
PROTOCOL/AMENDMENT NO.:   003 -01  
V181 -003-01FINAL PROTOCOL 14-JUL-2022
Note:  Determination of MAAEs is the responsibility of the investigator or qualified 
designee. Once identified, MAAEs should be reported to the Sponsor per the timeline for 
reporting AEs/SAEs .
10.3.[ADDRESS_463965] medical occurrence that, at any dose:
a.   Results in death
b.   Is life -threatening
â€¢The term â€œ life-threatening â€in the definition of â€œseriousâ€ refers to an event in which 
the participant was at risk of death at the time of the event. It does not refer to an 
event, which hypothetically might have caused death, if it were more severe.
c.   Requires inpatien t hospi[INVESTIGATOR_1081]
â€¢Hospi[INVESTIGATOR_19357], regardless of length of stay, even 
if the hospi[INVESTIGATOR_2138] a precautionary measure for continued observation. (Note: 
Hospi[INVESTIGATOR_19358] a pre -existing condition that has not 
worsened is not an SAE. )A pre -existing condition is a clinical condition that is 
diagnosed before the use of an MSD product and is documented in the participantâ€™s 
medical history.
d.   Results in persistent or significant disability/incapacity
â€¢The term disability means a substantial disruption of a personâ€™s ability to conduct 
normal life functions.
â€¢This definition is not intended to include experiences of relatively mi nor medical 
significance such as uncomplicated headache, nausea, vomiting, diarrhea, influenza, 
and accidental trauma (eg, sprained ankle) that may interfere with or prevent 
everyday life functions but do not constitute a substantial disruption.
e.   Is a congenital anomaly/birth defect
â€¢In offspring of participant taking the product regardless of time to diagnosis.
08MVGC
08SK8Z
PRODUCT:   V181  86
PROTOCOL/AMENDMENT NO.:   003 -01  
V181 -003-01FINAL PROTOCOL 14-JUL-2022
f.   Other important medical events
â€¢Medical or scientific judgment should be exercised in deciding whether SAE 
reporting is appropriate in other situations such as important medical events that may 
not be immediately life -threatening or result in death or hospi[INVESTIGATOR_63474] 1 
of the other outcomes listed in the above definition. These events should usually be 
considered serious.
Examples of such events include invasive or malignant cancers, intensive treatment in 
an emergency room or at home for allergic bronchospasm, blood dyscrasias or 
convulsions that d o not result in hospi[INVESTIGATOR_059], or development of drug dependency 
or drug abuse.
10.3.4 Additional Events Reported
Additional events that require r eporting
In addition to the above criteria, AEs meeting either of the below criteria, although not 
serious per ICH definition, are reportable to the Sponsor.
â€¢Is a cancer
â€¢Is associated with an overdose
10.3.5 Recording AE and SAE
AE and SAE r ecording
ï‚·    When an AE/SAE occurs, it is the responsibility of the investigator to review all 
documentation (eg, hospi[INVESTIGATOR_1088], laboratory, and diagnostics reports) related to 
the event.
ï‚·    
The investigator will record all relevant AE/SAE information on the AE 
CRFs /worksheets at each examination.
ï‚·    It is not acceptable for the investigator to send photocopi[INVESTIGATOR_10914]â€™s medical 
records to the Sponsor in lieu of completion of the AE CRF page.
ï‚·    There may be instances when copi[INVESTIGATOR_88650]. In this case, all participant identifiers, with the exception of the participant 
number, will be blinded on the copi[INVESTIGATOR_19361].
08MVGC
08SK8Z
PRODUCT:   V181  87
PROTOCOL/AMENDMENT NO.:   003 -01  
V181 -003-01FINAL PROTOCOL 14-JUL-2022
ï‚·    The investigator will attempt to establish a diagnosis of the event based on signs, 
symptoms, and/or other clinical information. In suc h cases, the diagnosis (not the 
individual signs/symptoms) will be documented as the AE/SAE.
Assessment of i ntensity
ï‚·    An event is defined as â€œserious â€when it meets at least 1 of the predefined outcomes as 
described in the definition of an SAE, not when it is rated as severe.
â€¢The investigator will make an assessment of intensity for each AE and SAE (and other 
reportable safety event) reported during the study and assign it to 1 of the following 
categories:
-Mild: An event that is easily tolerated by [CONTACT_2299], causing minimal discomfort 
and not interfering with everyday activities (for pediatric studies, awareness of 
symptoms, but easily tolerated).
-Moderate: An event that causes sufficient discomfort to interfere with normal 
everyday activities (for pediatric studies definitely acting like something is wrong).
-Severe: An event that prevents normal everyday activities. An AE that is assessed as 
sever e should not be confused with an SAE. Severe is a category utilized for rating 
the intensity of an event; and both AE and SAE can be assessed as severe (for 
pediatric studies, extremely distressed or unable to do usual activities).
â€¢Injection site erythema/ redness or swelling from the day of vaccination through Day 5 
postvaccination will be evaluated by [CONTACT_75367].
â€¢The investigator will make an assessment of overall intensity grade for each AE and SAE 
(and other reportable event) reported during the study. An overall intensity grade will be 
assigned to injection- site AEs, specific systemic AEs, other systemic AEs, and vital sign 
(temperature) AEs as shown in the following tables. The overall intensity grading scales 
used in this study follow the â€œFDA Guidan ce for Industry: Toxicity Grading Scale for 
Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials, 
September 2007.â€
08MVGC
08SK8Z
PRODUCT:   V181  88
PROTOCOL/AMENDMENT NO.:   003 -01  
V181 -003-01FINAL PROTOCOL 14-JUL-2022
Injection Site AE Overall Intensity Grading Scale
Injection -Site 
Reaction to Study 
Vaccine/PlaceboaMild
(Grade 1 )Moderate
(Grade 2 )Severe
(Grade 3 )Potentially Life 
Threatening
(Grade 4 )
Injection -site AEs occurring Days 1 through 5 following receipt of study vaccine/placebo
Pain/Tenderness Does not interfere 
with activityRepeated use of 
non-narcotic pain 
reliever >24 hours 
or interferes with 
activityAny use of 
narcotic pain 
reliever or prevents 
daily activityER visit or 
hospi[INVESTIGATOR_2666]/Redness â‰¤5 cm (size 
measured as A or
B)5.1 to 10 cm (size 
measured as C or 
D)>10 cm (size 
measured as Eâ†’ )Necrosis or 
exfoliative 
dermatitis or 
results in ER visit 
or hospi[INVESTIGATOR_370784] â‰¤5 cm (size
measured as A or 
B)5.1 to 10 cm (size
measured as C or 
D)>10 cm (size
measured as Eâ†’ )Necrosis or ER 
visit or 
hospi[INVESTIGATOR_93274]-narcotic pain 
reliever >24 hours 
or interferes with 
activityAny use of 
narcotic pain 
reliever or prevents 
daily activityER visit or 
hospi[INVESTIGATOR_63479] -site reaction that begins â‰¥6 days after receipt of study vaccine/placebo
Pain/Tenderness
Erythema/Redness
Swelling
OtherDoes not interfere 
with activityRepeated use of 
non-narcotic pain 
reliever >24 hours 
or interferes with 
activityAny us e of 
narcotic pain 
reliever or prevents 
daily activityER visit or 
hospi[INVESTIGATOR_93275]=adverse event; ER=emergency room; eVRC=electronic Vaccination Report Card
The overall intensity grading scales used in this study are adapted from the â€œFDA Guidance for Industry: Toxicity 
Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventative Vaccine Clinical Trials, September 
2007â€ [Food and Drug Administration 2007] .
aBased upon information provided by [CONTACT_370813]. Erythema/Redness
and Swelling are specific injection -site AEs with size designations of letters A (<2.5 cm), B (2.5 to 5 cm), C (5.1 to 
7.4 cm), D (7.5 to 10 cm), and E (>10 cm), based upon a graphic in the eVRC. If the participant has an ER visit or is 
hospi[INVESTIGATOR_63481] -site AE, that AE is to be assigned an intensity grade of 4, regardless of the size 
measured.
08MVGC
08SK8Z
PRODUCT:   V181  89
PROTOCOL/AMENDMENT NO.:   003 -01  
V181 -003-01FINAL PROTOCOL 14-JUL-2022
Specific Systemic AE Overall Intensity Grading Scale
Systemic 
(General)Mild 
(Grade 1)Moderate 
(Grade 2)Severe 
(Grade 3)Potentially Life 
Threatening
(Grade 4)
Headache No interference 
with activityRepeated use of non -
narcotic pain reliever 
>24hours or some 
interference with 
activitySignificant; any use 
of narcotic pain 
reliever or prevents 
daily activityER visit or 
hospi[INVESTIGATOR_93276]; 
prevents daily 
activityER visit or 
hospi[INVESTIGATOR_370785]; 
prevents daily 
activityER visit or 
hospi[INVESTIGATOR_370786]; 
prevents daily 
activityER visit or 
hospi[INVESTIGATOR_93277]; 
prevents daily 
activityER visit or 
hospi[INVESTIGATOR_370787]=emergency room
Other Systemic AE Overall Intensity Grading Scale
Systemic IllnessaMild 
(Grade 1)Moderate 
(Grade 2)Severe 
(Grade 3)Potentially Life 
Threatening
(Grade 4)b
Illness or clinical 
AE (as defined 
according to 
applicable 
regulations)No interference 
with activitySome interference 
with activity not 
requiring medical 
interventionPrevents daily 
activity and 
required medical 
interventionER visit or 
hospi[INVESTIGATOR_93278]=emergency room; eVRC=electronic Vaccination Report Card; SAE=serious adverse event
aBased upon information provided by [CONTACT_63555] -up period. For SAEs reported beyond the primary safety follow -up period, grading will be based upon the 
initial report and/or f ollow -up of the event.
bAEs resulting in death will be assessed as Grade 4.
Vital Sign (Temperature) Overall Intensity Grading Scale
Vital SignsaMild 
(Grade 1)Moderate 
(Grade 2)Severe 
(Grade 3)Potentially Life Threatening
(Grade 4)
Fever (Â°C)b
(Â°F)b38.0 to 38.4
100.4 to 101.138.5 to 38.9
101.2 to 102.039.0 to 40.0
102.1 to 104.0>40.0
>104.[ADDRESS_463966] for all vital sign requirements.
bOral temperature; no recent hot or cold beverages or smoking.
08MVGC
08SK8Z
PRODUCT:   V181  90
PROTOCOL/AMENDMENT NO.:   003 -01  
V181 -003-01FINAL PROTOCOL 14-JUL-2022
Assessment of c ausality
â€¢Did the Sponsorâ€™s product cause the AE?
â€¢The determination of the likelihood that the Sponsorâ€™s product caused the AE will be 
provided by [CONTACT_19427] a qualified physician. The investigatorâ€™s signed/dated 
initials on the source document or worksheet that supports the causality noted on the AE 
form, ensures that a medically qualified assessment of causality was done. This initialled 
document must be retain ed for the required regulatory time frame. The criteria below are 
intended as reference guidelines to assist the investigator in assessing the likelihood of a 
relationship between the test product and the AE based upon the available information.
â€¢The follow ing components are to be used to assess the relationship between the 
Sponsorâ€™s product and the AE ; the greater the correlation with the components and 
their respective elements (in number and/or intensity), the more likely the Sponsorâ€™s 
product caused the AE:
-Exposure: Is there evidence that the participant was actually exposed to the 
Sponsorâ€™s product such as: reliable history, acceptable compliance assessment 
(diary, etc.), seroconversion or identification of vaccine virus in bodily specimen?
-Time Course: Did the AE f ollow in a reasonable temporal sequence from 
administration of the Sponsorâ€™s product? Is the time of onset of the AE compatible 
with a vaccine -induced effect?
-Likely Cause: Is the AE not reasonably explained by [CONTACT_19511], other drug(s)/vaccine(s), or other host or environmental factors?
-Rechallenge: Was the participant re -exposed to the Sponsorâ€™s product in the study?
â—¦If yes, did the AE recur or worsen?
â—¦If yes, this is a positive rechallenge.
â—¦If no, this is a negative recha llenge.
(Note: This criterion is not applicable if: (1) the initial AE resulted in death or 
permanent disability, or (2) the study is a single -dose vaccine study; or (3) 
Sponsorâ€™s product(s) is/are used only 1 time.)
NOTE: IF A RECHALLENGE IS PLANNED FOR A N AE THAT WAS SERIOUS AND 
MAY HAVE BEEN CAUSED BY [CONTACT_26370]â€™S PRODUCT, OR IF RE -EXPOSURE 
TO THE SPONSORâ€™S PRODUCT POSES ADDITIONAL POTENTIAL SIGNIFICANT 
RISK TO THE PARTICIPANT THEN THE RECHALLENGE MUST BE APPROVED IN 
ADVANCE BY [CONTACT_370814], AND IF REQUIRED, THE 
IRB/IEC.
08MVGC
08SK8Z
PRODUCT:   V181  91
PROTOCOL/AMENDMENT NO.:   003 -01  
V181 -003-01FINAL PROTOCOL 14-JUL-2022
â€¢Consistency with study intervention profile: Is the clinical/pathological presentation of 
the AE consistent with previous knowledge regarding the Sponsorâ€™s product or drug class 
pharmacology or toxicology?
â€¢The assessment of relationship will be reported on the CRFs/worksheets by [CONTACT_26368] a qualified physician according to his/her best clinical judgment, 
including consideration of the above elements.
â€¢Use the following scale of criteria as guidance (not all cr iteria must be present to be 
indicative of a Sponsorâ€™s product relationship).
-Yes, there is a reasonable possibility of Sponsorâ€™s product relationship:
â—¦There is evidence of exposure to the Sponsorâ€™s product. The temporal sequence 
of the AE onset relative t o the administration of the Sponsorâ€™s product is 
reasonable. The AE is more likely explained by [CONTACT_1034]â€™s product than by 
[CONTACT_5748].
-No, there is not a reasonable possibility of Sponsorâ€™s product relationship:
â—¦Participant did not receive the Sponsorâ€™s product OR temporal sequence of the 
AE onset relative to administration of the Sponsorâ€™s product is not reasonable 
OR the AE is more likely explained by [CONTACT_26372]â€™s 
product. (Also entered for a participant with overdose without an associated 
AE.)
â€¢For each AE/SAE, the investigator must document in the medical notes that he/she has 
reviewed the AE/SAE and has provided an assessment of causality.
â€¢There may be situations in which an SAE has occurred and the investigator has minimal 
information to include in the initial report to the Sponsor. However, it is very important 
that the investigator always make an assessment of causality for every event before the 
initial transmission of the SAE data to the Sponsor.
â€¢The investigator may change his/her opi[INVESTIGATOR_9242] -up 
information and send an SAE follow -up report with the updated causality assessment.
â€¢The causality assessment is 1 of the criteria used when determining regulatory reporting 
requirements.
Follow -up of AE an d SAE
ï‚·    The investigator is obligated to perform or arrange for the conduct of supplemental 
measurements and/or evaluations as medically indicated or as requested by [CONTACT_19514]/or causality of the AE or SAE as fully as possible. This may 
08MVGC
08SK8Z
PRODUCT:   V181  92
PROTOCOL/AMENDMENT NO.:   003 -01  
V181 -003-01FINAL PROTOCOL 14-JUL-2022
include additional laboratory tests or investigations, histopathological examinations, or 
consultation with other health care professionals.
ï‚·    New or updated information will be recorded in the CRF.
ï‚·    The investigator will submit any updated SAE data to the Sponsor within 24 hours of 
receipt of the information.
10.3.6 Reporting of AE s, SAE s, and Other Reportable Safety Events to the Sponsor
AE, SAE, and o ther reportable safety event reporting to Sponsor via electronic d ata 
collection t ool
ï‚·    The primary mechanism for reporting to the Sponsor will be the EDC tool.
-Electronic reporting procedures can be found in the EDC data entry guidelines (or 
equivalent).
-If the electronic system is unavailable for more than 24 hours, then the site will 
use the paper AE Reporting form.
â—¦Reference Section 8.4.1 for reporting time requirements.
ï‚·    The site will enter the SAE data into the electronic system as soon as it becomes 
available.
ï‚·    After the study is completed at a given site, th e EDC tool will be taken off -line to prevent 
the entry of new data or changes to existing data.
ï‚·    If a site receives a report of a new SAE from a study participant or receives updated data 
on a previously reported SAE after the EDC tool has been taken o ff-line, then the site can 
report this information on a paper SAE form or by [CONTACT_756] (see next section).
ï‚·    Contacts for SAE reporting can be found in the Investigator Study File Binder (or 
equivalent).
SAE reporting to the Sponsor via paper CRF
ï‚·    If the EDC tool is not operational, facsimile transmission or secure e -mail of the SAE 
paper CRF is the preferred method to transmit this information to the Sponsor.
ï‚·    In rare circumstances and in the absence of facsimile equipment, notification by 
[CONTACT_9337] a copy of the SAE data collection tool sent by [CONTACT_19515].
08MVGC
08SK8Z
PRODUCT:   V181  93
PROTOCOL/AMENDMENT NO.:   003 -01  
V181 -003-01FINAL PROTOCOL 14-JUL-2022
ï‚·    Initial notification via telephone does not replace the need for the investigator to complete 
and sign the SAE CRF pages within the designated re porting time frames.
ï‚·    Contacts and instructions for SAE reporting and paper reporting procedures can be found 
in the Investigator Study File Binder (or equivalent) .
08MVGC
08SK8Z
PRODUCT:   V181  94
PROTOCOL/AMENDMENT NO.:   003 -01  
V181 -003-01FINAL PROTOCOL 14-JUL-2022
10.4 Appendix 4: Device Events, Adverse Device Events, and Medical Device 
Incidents: Definition s, Collection, and Documentation
Not applicable.
08MVGC
08SK8Z
PRODUCT:   V181  95
PROTOCOL/AMENDMENT NO.:   003 -01  
V181 -003-01FINAL PROTOCOL 14-JUL-2022
10.5 Appendix 5: Contraceptiv e Guidance
10.5.1 Definitions
Women of Childbearing Potential ( WOCBP )
A woman is considered fertile following menarche and until becoming postmenopausal 
unless permanently sterile (see below):
If fertility is unclear (eg, amenorrhea in adolescents or athletes) and a menstrual cycle cannot 
be confirmed before first dose of study intervention, additional evaluation should b e 
considered.
Women in the following categories are not considered WOCBP :
â€¢Premenarchal
â€¢Premenopausal female with 1 of the following:
-Documented hysterectomy
-Documented bilateral salpi[INVESTIGATOR_1656]
-Documented bilateral oophorectomy
For individuals with permanent infertility due to an alternate medical cause other than the 
above (eg, Mullerian agenesis, androgen insensitivity), investigator discretion should be 
applied to determining study entry.
Note: Documentation can come from the site personnelâ€™s review of the participantâ€™s 
medical records, medical examination, or medical history interview.
â€¢Postmenopausa l female
-A postmenopausal state is defined as no menses for 12 months without an alternative 
medical cause.
â—¦A high FSH level in the postmenopausal range may be used to confirm a 
postmenopausal state in women not using hormonal contraception or HRT. 
However, in the absence of [ADDRESS_463967]:   V181  96
PROTOCOL/AMENDMENT NO.:   003 -01  
V181 -003-01FINAL PROTOCOL 14-JUL-2022
10.5.2 Contraception Requirements
Contraceptives allowed during the study includea:
Highly Effective Contraceptive Methods That Have Low User Dependencyb
Failure rate of <1% per year when used consistently and correctl y.
â€¢Progestogen -only subdermal contraceptive implantc,d
â€¢IUSc
â€¢Non-hormonal IUD
â€¢Bilateral tubal occlusion
â€¢Azoospermic partner (vasectomized or secondary to medical cause)
This is a highly effective contraception method provided that the partner is the sole male sexual partner of 
the WOCBP and the absence of sperm has been confirmed. If not, an additional highly effective method 
of contraception should be used. A spermatogen esis cycle is approximately 90 day s.
Note: Documentation of azoospermia can come from the site personnelâ€™s review of the participantâ€™s 
medical records, medical examination, or medical history interview .
Highly Effective Contraceptive Methods That Are Use r Dependenta
Failure rate of <1% per year when used consistently and correctly .
â€¢Combined (estrogen -and progestogen -containing) hormonal contraceptionb,c
-Oral
-Intravaginal
-Transdermal
-Injectable
â€¢Progestogen -only hormonal contraceptionb,c
-Oral
-Injectable
Sexual Abstinence
â€¢Sexual abstinence is considered a highly effective method only if defined as refraining from heterosexual 
intercourse during the entire period of risk associated with the study intervention. The reliability of sexual 
abstinence needs to be evaluated in relation to the duration of the study and the preferred and usual 
lifestyle of the participant ..
a   Contraceptive use by [CONTACT_93339] .
b   Typi[INVESTIGATOR_63485] -use failure rates (ie, when used consistently and 
correctly ).
c   If locally required, in accordance with CTFG guidelines, acceptable contraceptive implants are limited to 
those which inhibit ovulation.
d   IUS is a progestin releasing IUD.
Note: The following are not acceptable methods of contraception:
-  Periodic abstinence (calendar, symptothermal, post -ovulation methods), withdrawal (coitus 
interruptus), spermicides only, and LAM.
-  Male condom with cap, diaphragm, or sponge with spermicide.
-  Male and female condom should not be used together (due to risk of failure with friction ).
08MVGC
08SK8Z
PRODUCT:   V181  97
PROTOCOL/AMENDMENT NO.:   003 -01  
V181 -003-01FINAL PROTOCOL 14-JUL-2022
10.6 Appendix 6: Collection and Management of Specimens for Future Biomedical 
Research
1.Definitions
a.   Biomarker: A biological molecule found in blood, other body fluids, or tissues 
that is a sign of a normal or abnormal process or of a condition or disease. A 
biomarker may be used to see how well the body responds to a treatment for a 
disease or condition .1
b.   Pharmacogenomics: The investigation of variations of DNA and RNA 
characteristics as related to drug/vaccine response.2
c.   Pharmacogenetics: A subset of pharmacogenomics, pharmacogenetics is the 
influence of variations in DNA sequence on drug/vaccine response.2
d.   DNA: Deoxyribonucleic acid.
e.   RNA: Ribonucleic acid.
2.  Scope of Future Biomedical Research
The specimens consented and/or collected in this study as outlined in Section 8.8
will be used in various experiments to understand:
â—¦The biology of how drugs/vaccines work
â—¦Biomarkers responsible for how a drug/vaccine enters and is removed by [CONTACT_165626]
â—¦Other pathways with which drugs/vaccines may interact
â—¦The biology of disease
The specimen(s) may be used for future assay development and/or drug/vaccine 
development.
It is now well recognized that information obtained from studying and testing 
clinical specimens offers unique opportunities to enhance our understanding of 
how individuals respond to drugs/vaccines, enhance our understanding of human 
disease and ultimately improve public health through development of novel 
treatments targeted to populations with the greatest need. All specimens will be 
used by [CONTACT_121311].
08MVGC
08SK8Z
PRODUCT:   V181  98
PROTOCOL/AMENDMENT NO.:   003 -01  
V181 -003-01FINAL PROTOCOL 14-JUL-2022
3.  Summary of Procedures for Future Biomedical Researc h
a.Participants for Enrollment
All participants enrolled in the clinical study will be considered for enrollment 
in future biomedical research .
b.Informed Consent
Informed consent for specimens (ie, DNA, RNA, protein, etc.) will be 
obtained during screening for protocol enrollment from all participants or 
legal guardians, at a study visit by [CONTACT_63559] d esignate. 
Informed consent for future biomedical r esearch should be presented to the 
participants on the visit designated in the SoA. If delayed, present consent at 
next possible Participant Visit. Consent forms signed by [CONTACT_370815].
A template of each study siteâ€™s approved informed consent will be stored in 
the Sponsorâ€™s clinical document repository.
c.eCRF Documentation for Future Biomedical Research Specimens
Documentat ion of participant consent for future biomedical research will be 
captured in the eCRFs . Any specimens for which such an informed consent 
cannot be verified will be destroyed.
d.Future Biomedical Research Specimen(s)
Collection of specimens for future biomedical r esearch will be performed as 
outlined i n the SoA. In general, if additional blood specimens ar e being 
collected for future biomedical r esearch, these will usually be obtained at a 
time when the participant is having blood drawn for other study purposes.
4.Confidential Participant Information f or Future Biomedical Research
In order to optimize the resea rch that can be conducted with future biomedical 
research specimens, it is critical to link participant s' clinical information with 
future test results. In fact ,little or no research can be condu cted without 
connecting the clinical study data to the specimen. The clinical data allow specific 
analyses to be conducted. Knowing participant characteristics like sex, ag e, 
medical history and intervention outcomes are critical to understanding clinical 
context of analytical results.
To maintain privacy of information collected from specimens obtained for future 
biomedical r esearch, the Sponsor has developed secure policies and procedures. 
All specimens will be single -coded per ICH E15 guidelines as descr ibed below.
08MVGC
08SK8Z
PRODUCT:   V181  99
PROTOCOL/AMENDMENT NO.:   003 -01  
V181 -003-01FINAL PROTOCOL 14-JUL-2022
At the clinical study site, unique codes will be placed on the future biomedical 
research specimens. This code is a random number which does not contain any 
personally identifying information embedded within it. The link (or key) between 
partic ipant identifiers and this unique code will be held at the study site. No 
personal identifiers will appear on the specimen tube.
5.Biorepository Specimen Usage
Specimens obtained for the Sponsor will be used for analyses using good 
scientific pra ctices. A nalyses utilizing the future biomedical r esearch specimens 
may be performed by [CONTACT_1034], or an additional third party (eg, a university 
investigator) designated by [CONTACT_1034]. The investigator conducting the analysis 
will follow the Sponsorâ€™s privacy and confidentiality requirements. Any 
contracted third party analyses will conform to the specific scope o f analysis 
outlined in the future biomedical research protocol and consent . Future 
biomedical r esearch specimens remaining with the third part y after specific 
analysis is performed will be reported to the Sponsor.
6.Withdrawal From Future Biomedical Research
Participants may withdraw their consent for future biomedical r esearch and ask 
that thei r biospecimens not be used for future biomedical r esearch. Participants 
may withdraw consent at any time by [CONTACT_370816]. If medical records for the main study are still available, the investigator 
will contact [CONTACT_75355] 
(clinical.specimen.m anagement@ MSD .com). Subsequently, the participant's 
specimens will be flagged in the biorepository and restricted to main study use 
only. If specimens were collected from study participants specifically for future 
biomedical r esearch, these specimens will be removed from the biorepository and 
destroyed. Documentation will be sent to the investigator confirming withdrawal 
and/or destruction, if applicable. It is the responsibility of the investigator to 
inform the participant of completion of the withdrawal and/or destruction, if 
applicable. Any analyses in progress at the time of request for 
withdrawal/destruction or already performed before the request being received by 
[CONTACT_370817]. No new analyses would be generated after the request is received.
In the event that the medical records for the main study are no longer available 
(eg, if the investigator is no longer required by [CONTACT_370818] s) or the specimens have been completely anonymized, there 
will no longer be a link between the participantâ€™s personal information and their 
specimens. In this situation, the request for withdrawal of consent and/or 
destruction cannot be processed.
08MVGC
08SK8Z
PRODUCT:   V181  100
PROTOCOL/AMENDMENT NO.:   [ADDRESS_463968] resu lts are accessible only to 
the authorized Sponsor representatives and the designated study administrator 
research personnel and/or collaborators. Database user authentication is highly 
secure, and is accomplished using network security policies and practic es based 
on international standards to protect against unauthorized access.
9.Reporting of Future Biomedical Research Data to Participants
No information obtained from exploratory laboratory studies will be reported to 
the participant, family, or physicia ns. Principle reasons not to inform or return 
results to the participant include: Lack of relevance to participant health, 
limitations of predictive capability, and concerns regarding misinterpretation.
If important research findings are discovered, the Sp onsor may publish results, 
present results in national meetings, and make results accessible on a public 
website in order to rapi[INVESTIGATOR_88651]. 
Participants will not be identified by [CONTACT_370819] a bout this 
study or in any other scientific publication or presentation.
10. Future Biomedical Research Study Population
Every effort will be made to recruit all participants diagnosed and treated o n 
Sponsor clinical studies for f uture biomedical r esearch.
11.Risks Versus Benefits of Future Biomedical Research
For future biomedical research, risks to the participant have been mini mized and 
are described in the future biomedical r esearch informed consent.
08MVGC
08SK8Z
PRODUCT:   V181  101
PROTOCOL/AMENDMENT NO.:   [ADDRESS_463969] security, policies, and procedures to address 
participant data privacy concerns. Data privacy risks are largely limited to rare 
situations involving possible breach of confidentiality. In this highly unlikely 
situation, there is risk that the information, like all me dical information, may be 
misused.
12.Questions
Any questions related to the future biomedical research should be e mailed directly 
to clinical.specimen.management@ MSD .com.
13.References
1.National Cancer Institute [Internet]: Available from 
https://www.cancer.gov/publications/dictionaries/cancer -terms?cdrid=[ZIP_CODE]
2.International Council on Harmoni sation [Internet] : E15: Definitions for 
Genomic Biomarkers, Pharmacogenomics, Pharmacogenetics, Genomic Data 
and Sample Coding Categories. Available from 
http://www.ich.org/products/guidelines/efficacy/efficacy -
single/article/definitions -for-genomic -biomarkers
-pharmacogenomics -
pharmacogenetics -genomic -data-and-sample -cod.html 
3.Industry Pharmacogenomics Working Group [Internet]: Understanding the 
Intent, Scope and Public Health Benefits of Exploratory Biomarker Research: 
A Guide for IRBs/IECs and Investigational Site Staff. Available at http://i-
pwg.org/ 
4.Industry Pharmacogenomics Working Group [Internet]: Pharmacogenomics 
Informational Brochure for IRBs/IECs and Investigational Site Staff. 
Available at http://i- pwg.org/
08MVGC
08SK8Z
PRODUCT:   V181  102
PROTOCOL/AMENDMENT NO.:   003 -01  
V181 -003-01FINAL PROTOCOL 14-JUL-2022
10.7 Appendix 7: Country -specific Requirements
Not applicable.
08MVGC
08SK8Z
PRODUCT:   V181  103
PROTOCOL/AMENDMENT NO.:   003 -01  
V181 -003-01FINAL PROTOCOL 14-JUL-2022
10.8 Appendix 8: Abbreviations
Abbreviation Expanded Term
AE Adverse event 
ADE Antibody -dependent enhancement
ApaT All-Participants -as-Treated
hCG human chorionic gonadotropin
Butantan -DV Butantan -Dengue Vaccine
CI Confidence interval
CRF Case report form 
CSR Clinical study report
CTFG Clinical Trials Facilitation Group
DENV Dengue virus
DHF Dengue hemorrhagic fever
DNA Deoxyribonucleic acid
DSS Dengue shock syndrome
DMC Data Monitoring Committee
ECI Event of clinical interest
eCRF Electronic case report form
EDC Electronic data capture
eDMC External Data Monitoring Committee
EEA European Economic Area
EMA European Medicines Agency
EOC Executive Oversight Committee 
eVRC Electronic Vaccination Report Card
FAS Full Analysis Set
FBR Future Biomedical Research
FDA Food and Drug Administration
FDAAA Food and Drug Administration Amendments Act
FSH Follicle stimulating hormone 
GCP Good Clinical Practice
GMO genetically modified organism
GMT Geometric mean titer
HEENT Head, eyes, ears, nose, and throat
HIV Human Immunodeficiency Virus
HRT Hormone replacement therapy
IB Investigatorâ€™s Brochure 
ICF Informed Consent Form
ICH International C ouncil on Harmoni sation
ICMJE International Committee of Medical Journal Editors
IEC Independent Ethics Committee
IMP Investigational Medicinal Product
IRB Institutional Review Board
IRT Intervention randomization system
IUD Intrauterine device
IUS Intrauterine system
LAM Lactational amenorrhea method
LATV Live-attenuated tetravalent vaccine
LLOQ Lower limit of qua ntification
MAAE Medically attended adverse event
NA Notapplicable
NIH National Institute of Health
08MVGC
08SK8Z
PRODUCT:   V181  104
PROTOCOL/AMENDMENT NO.:   [ADDRESS_463970]
WOCBP Woman/women of childbearing potential 
WT Wild -type
08MVGC
08SK8Z
PRODUCT:   V181  105
PROTOCOL/AMENDMENT NO.:   003 -01  
V181 -003-01FINAL PROTOCOL 14-JUL-2022
11 REFERENCES
[Alter, G. 2020] Alter G, Seder R. The power of antibody -
based surveillance [editorial]. N Engl J 
Med. In press 2020.[05LKN2]
[Anderson, K. B., et al 2007] Anderson KB, Chunsuttiwat S, Nisalak A, 
Mammen MP, Libraty DH, Rothman AL, 
et al. Burden of symptomatic dengue 
infection in children at primary school in 
Thailand: a prospective study. Lancet 
2007;369:1452- 9.[03RJZL]
[Bhatt, S., et al 2013] Bhatt S, Gething PW, Brady OJ, Messina 
JP, Farlow AW, Moyes CL, et al. The 
global distribution and burden of dengue 
[letter]. Nature. 2013 Apr 25;496:504 -7.[057ZS3]
[Casset ti, M. C. 2014] Cassetti MC, Halstead SB. Consultation 
on dengue vaccines: progress in 
understanding protection, 26- 28 June 
2013, Rockville, Maryland. Vaccine. 
2014;32:3115- 21.[080D80]
[Clopper, C. J. 1934] Clopper CJ, Pearson ES. The use of 
confidence o r fiducial limits illustrated in 
the case of the binomial. Biometrika 
1934;26(4):404- 13.[03Q0LW]
[Farrington, C. P. and 
Manning, G. 1990]Farrington CP, Manning G. Test statistics 
and sample size formulae for comparative 
binomial trials with null hypothesis of 
non-zero risk difference or non -unity 
relative risk. Statistics in Medicine 
1990;9:1447- 54.[03P8G5]
[Food and Drug 
Administration 2007]Food and Drug Administration. Guidance 
for industry: toxicity grading scale for 
healthy adult and adoles cent volunteers 
enrolled in preventive vaccine clinical 
trials. Rockville, MD. Sep 2007.[05B4S4]
08MVGC
08SK8Z
PRODUCT:   V181  106
PROTOCOL/AMENDMENT NO.:   003 -01  
V181 -003-01FINAL PROTOCOL 14-JUL-2022
[Food and Drug 
Administration 2019]Food and Drug Administration. 
Population pharmacokinetics: guidance 
for industry. Silver Spring, MD. Jul 2019.[05MKYS]
[Guzman, M. G., et al 2002] Guzman MG, Kouri G, Valdes L, Bravo J, 
Vazquez S, Halstead SB. Enhanced 
severity of secondary dengue -2 infections: 
death rates in 1981 and 1997 Cuban 
outbreaks. Rev Panam Salud Publica 
2002;11(4):223- 7.[03RK3C]
[Guzman, M. G., et al 2010] Guzman MG, Halstead SB, Artsob H, 
Buchy P, Farrar J, Gubler DJ, et al. 
Dengue: a continuing global threat. Nat 
Rev Micro 2010:S7- S16.[03RK08]
[Guzman, M. G., et al 2013] Guzman MG, Alvarez M, Halstead SB. 
Secondary infection as a risk factor for 
dengue hemorrhagic fever/dengue shock 
syndrome: an historical perspective and 
role of antibody- dependent enhancement 
of infection. Arch Virol. 2013;158:1445 -
59.[055JRP]
[Halstead, S. B. 2007] Halstead SB. Dengue. Lancet 
2007;370:1644- 52.[03RJ ZQ]
[Halstead, S. B. 2014] Halstead SB. Dengue antibody- dependent 
enhancement: knowns and unknowns. 
Microbiol spectr. 2014 Dec 12;2(6):[18 
p.].[058XX3]
[Halstead, S. B. and Deen, J. 
2002]Halstead SB, Deen J. The future of 
dengue vaccines. Lancet 2002;3 60:1243-
5.[03RHGX]
08MVGC
08SK8Z
PRODUCT:   V181  107
PROTOCOL/AMENDMENT NO.:   003 -01  
V181 -003-01FINAL PROTOCOL 14-JUL-2022
[Kallas, E. G., et al 2020] Kallas EG, Precioso AR, Palacios R, 
Thome B, Braga PE, Vanni T, et al. 
Safety and immunogenicity of the 
tetravalent, live -attenuated dengue 
vaccine Butantan -DV in adults in Brazil: a 
two-step, double -blind, randomized 
placebo -controlled phase [ADDRESS_463971] Dis. In press 2020.[05G8ZY]
[Miettinen, O. and Nurminen, 
M. 1985]Miettinen O, Nurminen M. Comparative 
analysis of two rates. Stat Med 
1985;4:213- 26.[03RVNK]
[Suaya, J. A., et al 2009] Suaya JA, Shepard DS, Siqueira JB, 
Martelli CT, Lum LCS, Tan LH, et al. 
Cost of dengue cases in eight countries in 
the Americas and Asia: a prospective 
study. Am J Trop Med Hyg 
2009;80(5):846- 55.[03RJZT]
[Tapia -Conyer, R., et al 2009] Tapia -Conyer R, MÃ©n dez-GalvÃ¡n JF, 
Gallardo- RincÃ³n H. The growing burden 
of dengue in Latin America. J Clin Virol 
2009;46(Suppl 2):S3- S6.[03RJZV]
[Thomas, S. J. and Endy, T. 
P. 2011]Thomas SJ, Endy TP. Vaccines for the 
prevention of dengue: development 
update. Hum Vaccin 2 011;7(6):674- 84.[03RJZW]
[Torres, J. R. and Castro, J. 
2007]Torres JR, Castro J. El impacto sanitario y 
econÃ³mico del dengue en LatinoamÃ©rica 
(The health and economic impact of 
dengue in Latin America). Cad SaÃºde 
PÃºblica, Rio de Janeiro 2007;23(Suppl 
1):S23-S31 (translated article).[03RK35]
[U.S. Department of Health 
and Human Services 2009]U.S. DHHS, FDA, CDER, CBER, CDRH. 
Guidance for industry: patient -reported 
outcome measures: use in medical product 
development to support labeling claims. 
2009.[04VZYM]
08MVGC
08SK8Z
PRODUCT:   V181  108
PROTOCOL/AMENDMENT NO.:   003 -01  
V181 -003-01FINAL PROTOCOL 14-JUL-2022
[Whitehorn, J. and Farrar, J. 
2010]Whitehorn J, Farrar J. Dengue. Br Med 
Bull 2010;95(1):161- 73.[03RJZZ]
[World Health Organization 
2009]World Health Organization.  Dengue: 
guidelines for diagnosis, treatment, 
prevention and control - new edition 
[2009].[03RK0R]
08MVGC
08SK8Z